Author: "Département de Médecine Nucléaire" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Département de Médecine Nucléaire"' showing total 647 results

Start Over Author "Département de Médecine Nucléaire"

647 results on '"Département de Médecine Nucléaire"'

1. Is Belgium still a iodine deficient country?

Author: ULB - Hôpital Erasme - Département de Médecine Nucléaire, Moreno-Reyes , Rodrigo, 11e Congrès UCL d'Endocrino-Diabétologie, ULB - Hôpital Erasme - Département de Médecine Nucléaire, Moreno-Reyes , Rodrigo, and 11e Congrès UCL d'Endocrino-Diabétologie
Abstract: In Belgium, fortification of bread with iodized salt has allowed iodine deficiency to be corrected in school-aged children. However, in pregnant women, the median urinary iodine concentration still indicates iodine deficiency, particularly in the first trimester of pregnancy., En Belgique, la fortification du pain avec le sel iodé a corrigé la carence en iode chez les enfants d’âge scolaire. Cependant, chez la femme enceinte, la médiane de la concentration urinaire en iode indique la persistance d’une carence en iode particulièrement au premier trimestre de la grossesse.
Published: 2014

2. Étude START (Salivary dysfuncTion After Radioiodine Treatment) : protocole d’étude

Author: Baudin, Clemence, Lussey-Lepoutre, Charlotte, Bressand, Alice, Buffet, Camille, Menegaux, Fabrice, Soret, Marine, Broggio, David, Bassinet, Celine, Huet, Christelle, Ory, Catherine, Leenhardt, Laurence, Armengol, Gemma, Bernier, Marie Odile, PSE-SANTE/SESANE/LEPID, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Sorbonne Université, Département de Médecine Nucléaire, AP-HP, Hôpital Pitié-Salpêtrière, F-75013, Paris, FrancePARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, F-75015, Paris, France, AMAREXIA France, F-75016, Paris, France, Unité Fonctionnelle Thyroïde et Tumeurs Endocrines (TTE) APHP, Sorbonne Université, Groupe de Recherche Clinique Tumeurs Thyroïdiennes n°16 F-75013, Paris, France, Unité Fonctionnelle Thyroïde et Tumeurs Endocrines (TTE) APHP, Sorbonne Université, Groupe de Recherche Clinique Tumeurs Thyroïdiennes n°16 F-75013, Paris, FranceSorbonne Université, Département de Chirurgie Générale, Viscérale et Endocrinienne, AP-HP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France, Sorbonne Université, Département de Médecine Nucléaire, AP-HP, Hôpital Pitié-Salpêtrière, F-75013, Paris, FranceSorbonne Université, CNRS, INSERM, Laboratoire d’Imagerie Médicale, LIB, F-75006, Paris, France, PSE-SANTE/SDOS/LEDI, PSE-SANTE/SDOS/LDRI, CEA DRF, iBFJ, iRCM, et Université Paris-Saclay, Fontenay-aux-Roses, France, Département de biologie animale, biologie végétale et écologie, Faculté des biosciences, Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalogne, Espagne, Laboratoire d épidémiologie des rayonnements ionisants (IRSN/PSE-SANTE/SESANE/LEPID), Service de recherche sur les effets biologiques et Sanitaires des rayonnements ionisants (IRSN/PSE-SANTE/SESANE), Institut de Radioprotection et de Sûreté Nucléaire (IRSN)-Institut de Radioprotection et de Sûreté Nucléaire (IRSN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de recherche clinique Tumeurs Thyroïdiennes (GRC 16 - GRC-TT), Sorbonne Université (SU), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'évaluation de la dose interne (IRSN/PSE-SANTE/SDOS/LEDI), Service de dosimétrie (IRSN/PSE-SANTE/SDOS), Laboratoire de dosimétrie des rayonnements ionisants (IRSN/PSE-SANTE/SDOS/LDRI), and Universitat Autònoma de Barcelona (UAB)
Subjects: [SDV]Life Sciences [q-bio]
Abstract: International audience; Contexte Suite au traitement par radioiode (I131) du cancer différencié de la thyroïde, les glandes salivaires peuvent être le siège d’inflammations, provoquant des troubles salivaires (TbS). L'incidence des TbS est mal connue ainsi que les facteurs de risque cliniques et génétiques. L’étude START vise à estimer l'incidence des TbS après traitement par radioiode, individualiser les facteurs de risque cliniques, biomoléculaires et biochimiques, et valider une méthode d’estimation dosimétrique pour calculer la dose reçue au niveau des glandes salivaires et analyser les relations dose-réponse.Matériel/Patients et MéthodesCette cohorte inclut des patients atteints d’un cancer différencié de la thyroïde et candidats à un traitement par I131 à l'hôpital Pitié-Salpêtrière. Trois visites sont organisées- avant traitement (T0), 6 mois (T6) et 18 mois post-traitement - et incluent des questionnaires validés. A T0 et T6, des prélèvements et des mesures dynamiques du flux salivaires sont réalisés. Des dosimètres sont placés le jour du traitement durant 5 jours au niveau des glandes salivaires et à la fourchette sternale. Des analyses génétiques et épigénétiques seront effectuées pour rechercher des biomarqueurs de prédisposition aux TbS. Le protocole a été enregistré sur clinicaltrials.gov (NCT04876287).Résultats attendusA la fin des inclusions (04/2021), 139 patients ont été inclus (45 et 94 patients traités par 1,1 et 3,7GBq respectivement). Le suivi à T6 est en cours. Les analyses statistiques permettront d'étudier les liens entre TbS et dose reçue par les glandes salivaires, en tenant compte des facteurs cliniques associés. L’impact sur la qualité de vie des patients sera analysé.
Published: 2021

3. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

Author: Anne Moreau, Olivier Casasnovas, Clément Bailly, Thomas Carlier, Steven Le Gouill, Thierry Lamy, Caroline Bodet-Milin, Françoise Kraeber-Bodéré, Olivier Hermine, Emmanuel Gyan, Michel Meignan, Anne Devillers, Barbara Burroni, Loïc Djaileb, Remy Gressin, Alina Berriolo-Riedinger, Catherine Thieblemont, Bernardo, Elizabeth, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, Gestes Médico-Chirurgicaux Assistés par Ordinateur - - CAMI2011 - ANR-11-LABX-0004 - LABX - VALID, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Nucléaire, Centre Georges-François Leclerc [Dijon] (CGFL), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'hématologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, LYSA Imaging (Créteil) (LYSA-IM), CHU Henri Mondor, Département de Pathologie [CHU Nantes], Service de Pathologie [AP-HP Hôpital Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de médecine Nucléaire [CHU Grenoble-Alpes], Centre Hospitalier Universitaire [Grenoble] (CHU), Service d'hématologie et d'Oncologie [CHU Grenoble], Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), CHU Pontchaillou [Rennes], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'onco-hématologie [AP-HP Hôpital Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Département d'Hématologie [CHU Nantes], This work has been supported in part by grants from the French National Agency for Research, called 'Investissements d’Avenir' IRON Labex nY ANR-11-LABX-0018-01, SIRIC ILIAD and Arronax Plus Equipex nY ANR-11-EQPX-0004, and by grants from DHU Oncogreffe (Nantes -France)., ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0004,CAMI,Gestes Médico-Chirurgicaux Assistés par Ordinateur(2011), CHU Henri Mondor [Créteil], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Laboratoire d'Hematologie [CHU Pontchaillou, Rennes] (Pôle de Biologie), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: medicine.medical_specialty, business.industry, Mantle Cell Lymphoma, LyMa Trial, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematology, medicine.disease, 3. Good health, SUV, 03 medical and health sciences, 0302 clinical medicine, Text mining, [SDV.CAN] Life Sciences [q-bio]/Cancer, 030220 oncology & carcinogenesis, medicine, Mantle cell lymphoma, In patient, Radiology, business, FDG-PET, Online Only Articles, Value (mathematics), ComputingMilieux_MISCELLANEOUS, 030215 immunology
Abstract: International audience
Published: 2020
Full Text: View/download PDF

4. Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients

Author: Lucie Planche, Françoise Kraeber-Bodéré, Thomas Carlier, Bastien Jamet, Caroline Bodet-Milin, Clément Bailly, Philippe Moreau, Cyrille Touzeau, Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Département de Biostatistiques [CHU Nantes] (PIMES), Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Saint-Jacques [CHU Nantes], Département d'Hématologie [CHU Nantes], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), This work has been supported by grants from the French National Agency for Research (Investissements D’Avenir), Labex IRON no. ANR-11-LABX-0018-01, Equipex Arronax Plus no. ANR-11-EQPX-0004 and SIRIC ILIAD no. INCa-DGOSInserm_12558., Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), and Bernardo, Elizabeth
Subjects: 0301 basic medicine, Cancer Research, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, medicine, Progression-free survival, ComputingMilieux_MISCELLANEOUS, Multiple myeloma, Positron Emission Tomography-Computed Tomography, business.industry, Disease progression, Follow up studies, Hematology, medicine.disease, 3. Good health, Transplantation, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Predictive value of tests, Fdg pet ct, Radiology, business
Abstract: Despite significant improvements in depth and duration of response due to the use of novel agent-based therapies, almost all patients with multiple myeloma (MM) ultimately relapse [1,2]. During dis...
Published: 2018
Full Text: View/download PDF

5. Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors

Author: Ludovic Ferrer, Bastien Jamet, Loïc Campion, Sylvie Girault, Thomas Carlier, Emmanuelle Bompas, Yann Venel, Caroline Rousseau, Fanny Borrely, Maxime Rousseau, Françoise Kraeber-Bodéré, Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Département de Médecine Nucléaire (NANTES - Médecine Nucléaire), Centre hospitalier universitaire de Nantes (CHU Nantes), Département d'Oncologie [Saint Herblain], Département de Médecine Nucléaire [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Département de Médecine Nucléaire [Tours], Hôpital Bretonneau [Tours], UNICANCER, Département de Physique [Saint Herblain], Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), and Bernardo, Elizabeth
Subjects: Oncology, medicine.medical_specialty, Multivariate analysis, [SDV.CAN]Life Sciences [q-bio]/Cancer, Ewing sarcoma family of tumors, 030218 nuclear medicine & medical imaging, survival analysis, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Progression-free survival, Stage (cooking), Survival analysis, business.industry, Cancer, Retrospective cohort study, computer.file_format, medicine.disease, FDG-PET/CT, 3. Good health, 030220 oncology & carcinogenesis, oncology, ICO, Sarcoma, prognosis, Nuclear medicine, business, computer, Research Paper
Abstract: // Bastien Jamet 1 , Thomas Carlier 2, 3 , Loic Campion 2, 4 , Emmanuelle Bompas 4 , Sylvie Girault 5 , Fanny Borrely 6 , Ludovic Ferrer 7 , Maxime Rousseau 1 , Yann Venel 6 , Francoise Kraeber-Bodere 1, 2, 3 and Caroline Rousseau 1, 2 1 Nuclear Medicine Unit, ICO Cancer Center Gauducheau, Saint Herblain, France 2 Nantes-Angers Cancer Research Center, INSERM U892, CNRS UMR 6299, University of Nantes, Nantes, France 3 Nuclear Medicine Unit, University Hospital, Nantes, France 4 Oncology Unit, ICO Cancer Center Gauducheau, Saint Herblain, France 5 Nuclear Medicine Unit, ICO Cancer Center Papin, Angers, France 6 Nuclear Medicine Unit, University Hospital Bretonneau, Tours, France 7 Physics Unit, ICO Cancer Center Gauducheau, Saint Herblain, France Correspondence to: Bastien Jamet, email: bastien.jamet@chu-nantes.fr Keywords: FDG-PET/CT, oncology, Ewing sarcoma family of tumors, survival analysis, prognosis Received: May 11, 2017 Accepted: June 27, 2017 Published: August 18, 2017 ABSTRACT Purpose: The aim of this retrospective study was to determine, at baseline, the prognostic value of different FDG-PET/CT quantitative parameters in a homogenous Ewing Sarcoma Family of Tumors (ESFT) adult population, compared with clinically relevant prognostic factors. Methods: Adult patients from 3 oncological centers, all with proved ESFT, were retrospectively included. Quantitative FDG-PET/CT parameters (SUV (maximum, peak and mean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the primary lesion of each patient were recorded before treatment, as well as usual clinical prognostic factors (stage of disease, location, tumor size, gender and age). Then, their relation with progression free survival (PFS) and overall survival (OS) was evaluated. Results: 32 patients were included. Median age was 21 years (range, 15 to 61). Nineteen patients (59%) were initially metastatic. On multivariate analysis, high SUV max remained independent predictor of worst OS (p=0.02) and PFS (p=0.019), metastatic disease of worst PFS (p=0.01) and high SUVpeak of worst OS (p=0.01). Optimal prognostic cut-off of SUV peak was found at 12.5 in multivariate analyses for PFS and OS ( p =0.0001). Conclusions: FDG-PET/CT, recommended at ESFT diagnosis for initial staging, can be a useful tool for predicting long-term adult patients outcome through semi-quantitative parameters.
Published: 2017

6. Radioimmunoconjugates for treating cancer: recent advances and current opportunities

Author: Caroline Bodet-Milin, François Guérard, Françoise Kraeber-Bodéré, Clément Bailly, Michel Chérel, Alain Faivre-Chauvet, Mickaël Bourgeois, Mathieu Frindel, Bernardo, Elizabeth, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Cyclotron ARRONAX [Saint-Herblain], ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), Département de Médecine Nucléaire (NANTES - Médecine Nucléaire), Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)
Subjects: 0301 basic medicine, medicine.medical_specialty, Immunoconjugates, Clinical Biochemistry, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Recombinant antibodies, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Antibodies monoclonal, Neoplasms, Drug Discovery, medicine, Humans, cancer, Medical physics, Pretargeting, Pharmacology, business.industry, Antibodies, Monoclonal, Cancer, medicine.disease, 3. Good health, 030104 developmental biology, Isotope Labeling, Positron-Emission Tomography, 030220 oncology & carcinogenesis, Nuclear medicine, Immunology, radioimmunotherapy, monoclonal antibodies, immunoPET, business, Haematological disorders
Abstract: International audience; Introduction: Radioimmunoconjugates have been used for 30 years to diagnose and treat cancer. For many years, the use of these therapeutic tools has been limited to haematological disorders, such as non-Hodgkin's lymphoma, given that they have only had a moderate effect on solid tumours. Areas covered: Recently, several strategies have revived the potential therapeutic application for radioimmunoconjugates. In this review, the authors review the advances in immunological engineering to develop new tools like monoclonal antibodies and their derivatives. Then, the authors summarize the development of radionuclides, the use of recombinant antibodies, pretargeting approaches, and dose fractionation techniques, providing opportunities for both therapeutic and diagnostic applications. Expert opinion: Radioimmunoconjugates used in nuclear medicine have entered a new era of development. These advances give rise to a variety of opportunities in the management of various cancers, where the radiolabelled antibodies may be particularly useful in immuno-specific phenotypic imaging e.g. companion diagnostics. Concerning therapeutic applications, radioimmunoconjugates have demonstrated their efficacy in the treatment of both haematological malignancies and solid tumours. Recent procedural developments are of great interest in optimising oncological targeted therapies. In the field of cancer theranostics, we believe that radioimmunoconjugated compounds are likely to play a large part in near future. ARTICLE HISTORY
Published: 2017
Full Text: View/download PDF

7. 18F-FDG PET/CT in multiple myeloma: critical insights and future directions

Author: Clément Bailly, Thomas Carlier, Bastien Jamet, Françoise Kraeber-Bodéré, Philippe Moreau, Caroline Bodet-Milin, Cyrille Touzeau, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Département d'Hématologie [CHU Nantes], Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, This work was supported in part by grants from the French National Agency for Research (Investissements d’Avenir, IRON Labex grant no. ANR-11-LABX-0018-01, and ArronaxPlus Equipex grant no. ANR-11-EQPX-0004), and from the Institut National du Cancer (grant no. INCa-DGOS-Inserm_12558, SIRIC ILIAD)., ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), Bernardo, Elizabeth, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: 0303 health sciences, medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.medical_treatment, Induction chemotherapy, [SDV.CAN]Life Sciences [q-bio]/Cancer, General Medicine, Hematopoietic stem cell transplantation, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Positron emission tomography, 030220 oncology & carcinogenesis, medicine, Radiology, Nuclear Medicine and imaging, Fdg pet ct, Radiology, business, Multiple myeloma, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Positron Emission Tomography-Computed Tomography
Abstract: International audience; no abstract
Published: 2019
Full Text: View/download PDF

8. Interest of FDG-PET in the Management of Mantle Cell Lymphoma

Author: Clément Bailly, Thomas Carlier, Cyrille Touzeau, Nicolas Arlicot, Françoise Kraeber-Bodéré, Steven Le Gouill, Caroline Bodet-Milin, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Laboratoire d'Hematologie [CHU de Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, This work has been supported in part by grants from the French National Agency for Research called, Investissements d’Avenir IRON Labex n◦ ANR-11-LABX-0018-01 and ArronaxPlus Equipex n◦ ANR-11-EQPX-0004., ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), Bernardo, Elizabeth, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: Oncology, medicine.medical_specialty, mantle cell lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, Review, Disease, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Intensive therapy, hemic and lymphatic diseases, Medicine, In patient, Prospective cohort study, FDG-PET, neoplasms, lcsh:R5-920, Potential impact, business.industry, General Medicine, staging, medicine.disease, 3. Good health, Lymphoma, SUV, 030220 oncology & carcinogenesis, Treatment strategy, Mantle cell lymphoma, lcsh:Medicine (General), business, therapeutic evaluation, 030215 immunology
Abstract: International audience; FDG-PET changed response assessment and therapy strategy in diffuse large B-cell lymphoma and Hodgkin disease lymphoma. The value of FDG-PET evaluation in MCL has not been extensively studied and a recent expert consensus highlighted the need for more studies addressing this question. Data of the literature show the value of FDG-PET at baseline in patients with MCL, underlining the good sensitivity of this examination for the initial staging of this pathology, but also the potential impact of semi-quantitative analysis in this indication. The determination of SUVmax at diagnosis might indeed provide important prognostic information. Some studies also suggest the potential value of early and end-of-treatment metabolic assessment in MCL, but these results need to be validated in standardized prospective studies. These results also underlie the need to integrate FDG-PET results into MCL treatment strategy to improve disease management in identifying patients who might benefit from more intensive therapy.
Published: 2019
Full Text: View/download PDF

9. Prédiction de la progression chez des patients atteints de myélome multiple par 'Random Survival Forest'

Author: Morvan, Ludivine, Mateus, Diana, Bailly, Clément, Jamet, Bastien, Bodet-Milin, Caroline, Moreau, Philippe, Touzeau, Cyrille, Kraeber-Bodéré, Françoise, Carlier, Thomas, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Laboratoire des Sciences du Numérique de Nantes (LS2N), IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Département d'Hématologie [CHU Nantes], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Signal, IMage et Son (SIMS ), Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Département de Médecine Nucléaire (NANTES - Médecine Nucléaire), Service de Médecine Nucléaire [CHU Nantes], Département d'Hématologie Clinique [CHU Nantes], Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Nantes (UN)-Université de Nantes (UN)-École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Carlier, Thomas, Morvan, ludivine, Signal, IMage et Son (LS2N - équipe SIMS ), and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: [INFO.INFO-AI] Computer Science [cs]/Artificial Intelligence [cs.AI], [SDV.IB] Life Sciences [q-bio]/Bioengineering, [INFO.INFO-TS] Computer Science [cs]/Signal and Image Processing, [SDV]Life Sciences [q-bio], [INFO.INFO-IM] Computer Science [cs]/Medical Imaging, [SDV.CAN]Life Sciences [q-bio]/Cancer, [STAT.ML] Statistics [stat]/Machine Learning [stat.ML], Random Survival Forest, [INFO.INFO-AI]Computer Science [cs]/Artificial Intelligence [cs.AI], [SDV] Life Sciences [q-bio], [INFO.INFO-TI] Computer Science [cs]/Image Processing [eess.IV], [SDV.CAN] Life Sciences [q-bio]/Cancer, [STAT.ML]Statistics [stat]/Machine Learning [stat.ML], [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Myélome multiple, Analsye de survie, [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, [SDV.IB]Life Sciences [q-bio]/Bioengineering
Abstract: International audience; Contexte L'imagerie TEP-FDG corps entier procure des informations pronostiques dans le bilan initial et le suivi thérapeutique des patients atteints de myélome multiple (MM). Etat de l'art Les biomarqueurs par imagerie TEP ont été peu étudiés dans ce contexte et souvent en utilisant des méthodes de Cox et de Kaplan-Meier. Cependant, une approche de type "Random Survival Forest" (RSF), peut fournir un procédé plus robuste pour l'analyse de la survie et n'est pour le moment pas étudié dans le cadre du MM et de l'imagerie TEP. Proposition Nous proposons une méthode pour la prédiction de la progression dans le contexte du MM en utilisant des RSF avec la méthode de sélection par 'Variable importance' (VIMP) [Ishwaran et al., Annals of Applied Statistics, 2008]. Matériel et méthodes 1) Les données • Etude multicentrique et prospective, IMAJEM [Moreau et al. J Clin Oncol 2017] • 99 patients • Prise en compte des caractéristiques cliniques et d'imagerie. 2) La méthode Résultats 2) Caractéristiques prédictives Figure 4 : Diagramme des caractéristiques trouvées comme prédictives par la méthode VIMP (Le nombre optimal de features gardées est entre 5 et 7.) Résultats 1) Evaluation de la méthode Figure 2 : Erreur de prédiction sur 50 itérations, en fonction de la méthode. GB : gradient boosting machine with Cox, GBCI : gradient boosting machine for concordance index, Lasso : Lasso-cox, Our method : sélection VIMP plus RSF, Without : RSF sans sélection préalable. Figure 3 : A) Courbe de Kaplan Meier dans deux groupes de pronostic obtenues sur le set de test (en rose : Bon pronostic, en bleu : mauvais pronostic). Erreur : 0,30, p-value = 0,0058, valeur log-rank = 7,6, nombre de patients par groupe = 12. B) P-value calculée pour 50 itérations pour différentes méthode de sélection suivies d'une RSF. Our method : VIMP, VH : Variable-Hunting, MD : Minimal Depth, Without : sans sélection. Conclusions et perspectives La méthode proposée permet de décrire un modèle plus performant que les approches conventionnelles pour la prédiction au bilan initial de la survie sans progression des patients atteints de myléome multiple. Nous avons montré qu'il était possible de correctement séparer deux classes de patients (bon/mauvais pronostic) à partir de données indépendantes. Elle permet également de déterminer les paramètres clinico-biologiques et par imagerie les plus prédictifs de la progression. Par la suite, plus de patients et de paramètres vont être inclus avec notamment des caractéristiques radiomiques. Cette approche peut être généralisée à d'autres pathologies. Remerciements : Ce travail a été partiellement financé par SIRIC ILIAD et MILCOM Connect Talent.
Published: 2019

10. Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients

Author: Franéoise Kraeber-Bodéré, Beatrice Mahe, Steven Le Gouill, Antoine Bonnet, Pierre Peterlin, Caroline Bodet-Milin, Philippe Moreau, Cyrille Touzeau, Amandine Le Bourgeois, Thomas Gastinne, Alice Garnier, Nicolas Blin, Louise Bouard, Thierry Guillaume, Patrice Chevallier, Anne Lok, Viviane Dubruille, Clément Bailly, Marie C. Béné, Département d'Hématologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Médecine Nucléaire [CHU Nantes], Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Nuclear Oncology (CRCINA-ÉQUIPE 13), Département d'hématologie et de biologie [CHU Nantes], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, This work was supported in part by grants from the French National Agency for Research ('Investissementsd’Avenir' IRON Labex no. ANR-11-LABX-0018-01 and ArronaxPlusEquipex no. ANR-11-EQPX-0004)., ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Bernardo, Elizabeth, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, and Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID
Subjects: Adult, Male, medicine.medical_specialty, Time Factors, Lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Young Adult, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Fluorodeoxyglucose F18, Predictive Value of Tests, Recurrence, Internal medicine, Positron Emission Tomography Computed Tomography, medicine, T-cell lymphoma, Humans, Transplantation, Homologous, Adult Hodgkin Lymphoma, Aged, Retrospective Studies, Transplantation, Hematology, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, (18)F-FDG-PET CT, Middle Aged, medicine.disease, Survival Analysis, 3. Good health, Allogeneic stem cell transplantation, Deauville scale, 030220 oncology & carcinogenesis, Cohort, Female, Radiology, business, 030215 immunology
Abstract: International audience; The impact of early fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported. This retrospective study included all adult Hodgkin lymphoma (HL) or non-Hodgkin lymphoma(NHL) patients (>18 years old) who benefited from FDG PET-CT before (within 1 month) and/or early (+3 months and within +6 to 9 months) after allogeneic stem cell transplantation in our institution between 2005 and 2015 and who were still without documented progression or relapse at the time of the FDG PET-CT. All FDG PET-CT were reviewed by a nuclear medicine expert in hematology and restaged according to the Deauville scale. FDG-PET CT was considered positive when the uptake was higher than liver background (Deauville score 4). The primary objective was to study the impact of pre-and post-transplant FDG PET-CT on lymphoma-free survival (LFS) and overall survival (OS). Inclusion criteria were fulfilled for 103 patients (69 men; median age, 51.6 years old; range, 22 to 67). Diagnoses were high-grade NHL (n = 47), low-grade NHL (n = 6), T cell lymphoma (n = 34), and HL (n = 16). More than half of the patients were in complete remission at the time of transplant (n = 56). A reduced-intensity conditioning regimen was applied in most cases (n = 90). With a median follow-up of 49.5 months (range, 6 to 140.5) for alive patients, median 3-year OS and LFS were, respectively, 81% (range, 71% to 87%) and 65% (range, 54% to 74%) for the entire cohort. In multivariate analysis, positive FDG PET-CT at 3 months was the strongest independent factor significantly associated with poorer LFS (hazard ratio, 9.22; 95% confidence interval, 1.88 to 645.2; P = .006). FDG PET-CT positivity at 3 months appears to be highly predictive of LFS in patients after allogeneic transplantation and may help to guide strategies to prevent relapse. These results need to be validated prospectively.
Published: 2018
Full Text: View/download PDF

11. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma

Author: Veronique Edeline, S. Becker, T. Vander Borght, Olivier Casasnovas, Alina Berriolo-Riedinger, Service de Médecine Nucléaire, Centre Georges-François Leclerc [Dijon] (CGFL), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Département de médecine nucléaire (CHU UCL Namur), CHU UCL Namur, Namur Research Institute for Life Sciences (NARILIS), Département de médecine nucléaire (Institut Curie, Saint-Cloud), and Institut Curie [Paris]
Subjects: medicine.medical_specialty, Interim PET, Neoplasm, Residual, PET-CT, Clinical Decision-Making, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, 030218 nuclear medicine & medical imaging, TEP-scanographie, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, medicine, Humans, Radiology, Nuclear Medicine and imaging, Neoplasm Staging, Fluorodeoxyglucose, Lymphome de Hogkin, Lymphatic Irradiation, business.industry, Advanced stage, Complete remission, Hematopoietic Stem Cell Transplantation, Gold standard (test), Prognosis, Hodgkin Disease, 3. Good health, Treatment management, Oncology, Imagerie, 030220 oncology & carcinogenesis, Hodgkin lymphoma, Fdg pet ct, Radiology, Tomography, Lymph Nodes, Radiopharmaceuticals, business, medicine.drug, Radiotherapy, Image-Guided
Abstract: IF 1.128; International audience; Fluorodeoxyglucose (FDG) positons emission tomography (PET)-computed tomography (CT) is used in many ways at baseline and during the treatment of patients with Hodgkin lymphoma. Many properties of the technique are used in the different steps of patient's management. Initial staging with PET-CT is more accurate than conventional imaging and PET-CT also became the gold standard imaging at the end of treatment with a negative PET-CT mandatory for reaching a complete remission. Early assessment of response by PET-CT is one of the most powerful prognostic factors for progression-free survival of patients with localized and advanced stages and allows guiding treatment. Conversely, previous studies showed that there is no role of FDG PET-CT for the patient's follow-up.; La tomographie par émission de positrons (TEP)-tomodensitométrie au fluorodésoxyglucose est utilisée de différentes manières au moment du diagnostic et pendant le traitement des lymphomes de Hodgkin. Plusieurs particularités de la TEP sont utilisées à différentes étapes de la prise en charge des patients. Lors du bilan initial, la TEP-tomodensitométrie est plus performante que les techniques d’imageries conventionnelles, mais l’est aussi en fin de traitement, un examen normal étant indispensable pour affirmer l’obtention d’une rémission complète. L’évaluation précoce en cours de traitement est un des facteurs pronostiques les plus puissants pour la survie sans progression et pour guider le traitement dans les maladies localisées et disséminées. À l’inverse, la TEP-tomodensitométrie n’a pas de rôle dans le suivi des patients.
Published: 2018
Full Text: View/download PDF

12. Sensitivity of pretargeted immunoPET using 68 Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18 FDG PET-CT

Author: Foubert, Fanny, Gouard, Sebastien, Sai-Maurel, Catherine, Cherel, Michel, Faivre-Chauvet, Alain, Goldenberg, David, Barbet, Jacques, Bailly, Clément, Bodet-Milin, Caroline, Carlier, Thomas, Kraeber-Bodéré, Françoise, Touchefeu, Yann, Frampas, Eric, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Département d'hépato-gastro-entérologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut des Maladies de l’Appareil Digestif [CHU Nantes], Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), IBC Pharmaceuticals Inc [Morris Plains, NJ, USA], Immunomedics Inc. [Morris Plains, NJ, USA], GIP ARRONAX [Nantes] (Saint-Herblain), Université de Nantes (UN), Département de Radiologie [CHU Nantes], This work has been supported in part by grants from the French National Agency for Research called 'Investissements d'Avenir' Labex IRON n°ANR-11-LABX-0018-01 and Equipex ArronaxPlus n°ANR-11-EQPX-0004, and by a grant from the 'DHU Oncogreffe' of the Nantes University Hospital., ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), Bernardo, Elizabeth, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Subjects: [SDV.CAN] Life Sciences [q-bio]/Cancer, carcinoembryonic antigen, immuno-PET, colonic cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, liver metastases, 18 FDG-PET
Abstract: International audience; ABSTRACT Purpose: The aim of this study was to compare the performances pretargeted immunoPET 68 Ga-PETimaging (68 Ga-pPET) with anti carcino-embryonic antigen (CEA) and anti-histamine-succinyl-glycine (HSG) recombinant humanized bispecific monoclonal antibody (TF2) and 68 Ga-labeled HSG peptide (IMP288) to conventional 18 FDG-PET in an orthotopic murine model of liver metastases of human colonic cancer. Methods: Hepatic tumor burden following intra-portal injection of luciferase-transfected LS174T cells in nude mice was confirmed using bioluminescence. One group of animals was injected intravenously with TF2 and with 68 Ga-IMP288 24 hours later (n=8). Another group received 18 FDG (n=8), and a third had both imaging modalities (n=7). PET acquisitions started 1 hour after injection of the radioconjugate. Biodistributions in tumors and normal tissues were assessed one hour after imaging. Results: Tumor/organ ratios were significantly higher with 68 Ga-pPET compared to 18 FDG-PET (P
Published: 2018
Full Text: View/download PDF

13. Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer

Author: Cédric Mathieu, Clément Bailly, Françoise Kraeber-Bodéré, D. Rusu, Mathilde Colombié, T. Rousseau, Ludovic Ferrer, N. Rousseau, Caroline Rousseau, Loïc Campion, Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Statistiques [Saint Herblain], Clinique Urologique Nantes Atlantis [Saint Herblain], Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Physique [Saint Herblain], This work was supported by grants from the French National Agency for Research called BInvestissements d’Avenir, Labex IRON no. ANR-11-LABX-0018-01 and Equipex ArronaxPlus no. ANR-11- EQPX-0004., ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), Bernardo, Elizabeth, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, and Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID
Subjects: Biochemical recurrence, medicine.medical_specialty, Multivariate analysis, PET/CT, [SDV.CAN]Life Sciences [q-bio]/Cancer, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, medicine, Radiology, Nuclear Medicine and imaging, Metabolic parameters, Lymph node, PET-CT, business.industry, 18F-Choline, Retrospective cohort study, General Medicine, Nomogram, medicine.disease, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Recurrent prostate cancer, Radiology, business, Nuclear medicine
Abstract: International audience; PURPOSE: To evaluate the therapeutic impact of (18)F-fluorocholine (FCH) PET/CT in biochemical recurrent prostate cancer (PC) and to investigate the value of quantitative FCH PET/CT parameters in predicting progression-free survival (PFS).METHODS: This retrospective study included 172 consecutive patients with PC who underwent FCH PET/CT for biochemical recurrence. Mean rising PSA was 10.7 ± 35.0 ng/ml. Patients with positive FCH PET were classified into three groups: those with uptake only in the prostatic bed, those with locoregional disease, and those with distant metastases. Referring physicians were asked to indicate the hypothetical therapeutic strategy with and without the FCH PET/CT results. Clinical variables and PET parameters including SUVmax, SUVpeak, SUVmean, total lesion choline kinase activity (TLCKA) and standardized added metabolic activity (SAM) were recorded and a multivariate analysis was performed to determine the factors independently predicting PFS.RESULTS: In 137 of the 172 patients, the FCH PET/CT scan was positive, and of these, 29.9 % (41/137) had prostatic recurrence, 42.3 % (58/137) had pelvic lymph node recurrence with or without prostatic recurrence, and 27.7 % (38/137) had distant metastases. The FCH PET/CT result led to a change in treatment plan in 43.6 % (75/172) of the 172 patients. Treatment was changed in 49.6 % (68/137) of those with a positive FCH PET/CT scan and in 20 % (7/35) of those with a negative FCH PET/CT scan. After a median follow-up of 29.3 months (95 % CI 18.9 - 45.9 months), according to multivariate analysis age
Published: 2015
Full Text: View/download PDF

14. Tumor Immunotargeting Using Innovative Radionuclides

Author: Jean-François Chatal, Eric Frampas, Nicolas Chouin, Caroline Bodet-Milin, Jacques Barbet, Cédric Mathieu, Thomas Carlier, François Guérard, Caroline Rousseau, Alain Faivre-Chauvet, Michel Chérel, Françoise Kraeber-Bodéré, Ferid Haddad, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Médecine Nucléaire [ICO-Site Gauducheau, Saint-Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Département de Radiologie [CHU Nantes], Animaux modèles pour la recherche en oncologie comparée (AMaROC), Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS), Département de Physique [Nantes] (GIP Arronax), ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), This work has been supported in part by a grant from the French National Agency for Research, called 'Investissements d’Avenir' no. ANR-11-LABX-0018-01., ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), Bernardo, Elizabeth, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, and École nationale vétérinaire, agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)
Subjects: Diagnostic Imaging, medicine.medical_specialty, alpha particle-emitting radionuclides, medicine.medical_treatment, Context (language use), [SDV.CAN]Life Sciences [q-bio]/Cancer, Review, Catalysis, Radiolabeled Antibodies, Inorganic Chemistry, lcsh:Chemistry, [SDV.CAN] Life Sciences [q-bio]/Cancer, Neoplasms, Medical imaging, Humans, Medicine, Medical physics, Physical and Theoretical Chemistry, Radionuclide Imaging, Molecular Biology, lcsh:QH301-705.5, Spectroscopy, innovative radionuclides, Pretargeting, Radioisotopes, Tumor imaging, business.industry, Organic Chemistry, Antibodies, Monoclonal, General Medicine, Pet imaging, 3. Good health, Computer Science Applications, lcsh:Biology (General), lcsh:QD1-999, Radioimmunotherapy, immuno-PET, radioimmunotherapy, Personalized medicine, business, alpha-immunotherapy
Abstract: International audience; This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.
Published: 2015
Full Text: View/download PDF

15. Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

Author: Isabelle Soubeyran, Anne Moreau, David M. Goldenberg, Amandine Pallardy, Jean-Philippe Vuillez, Jacques Barbet, Loïc Campion, Olivier Tournilhac, Nadine Morineau, Caroline Bodet-Milin, Krimo Bouabdallah, Thierry Lamy, Etienne Garin, Philippe Moreau, Steven Le Gouill, Pierre Soubeyran, Pierre-Yves Salaun, Hervé Maisonneuve, Anne-Laure Cazeau, Bénédicte Deau, Sophie Sadot, Valérie Gouilleux-Gruart, Françoise Kraeber-Bodéré, Henry Jardel, Remy Gressin, Emmanuel Gyan, Christian Berthou, Etienne Daguindau, William A. Wegener, Marie-Pierre Moles, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'hématologie, Centre hospitalier La Roche-Sur-Yon, Centre René Gauducheau, CRLCC René Gauducheau, Plateforme de génétique moléculaire des cancers d'Aquitaine, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias - Clermont Auvergne (CHELTER), Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Service de Médecine Interne, CH Bretagne Atlantique, Centre Catherine-de-Sienne [Nantes] (CCS), Université Mohamed Boudiaf de M'sila, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Grenoble-Hôpital Michallon, Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Institut de Recherche sur la Fusion par confinement Magnétique (IRFM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Microenvironnement et remodelage, Service de médecine nucléaire, Centre régional de lutte contre le cancer-Centre régional de lutte contre le cancer, Radiopharmaceutiques biocliniques, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Développement normal et pathologique des lymphocytes et signalisation, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Accélérateur pour la Recherche en Radiochimie et Oncologie [Nantes Atlantique] (GIP ARRONAX), Université de Nantes (UN)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Garden State Cancer Center (GSCC), Garden State Cancer Center, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Service de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Onco-hématologie [La Roche sur Yon], Centre Hospitalier Universitaire de Nantes, Génétique tumorale - Pathologie, UNICANCER-UNICANCER-CHU Bordeaux [Bordeaux], CIC Plurithématique de Nantes, Institut National de la Santé et de la Recherche Médicale (INSERM)-Ministère des Affaires sociales et de la Santé-Direction générale de l'offre de soins (DGOS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Médecine interne - Maladies hématologiques - Maladies infectieuses [Vannes], Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), PRES Université Nantes Angers Le Mans (UNAM), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de cancérologie et d'hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de Médecine Nucléaire (NANTES - Médecine Nucléaire), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Médecine Nucléaire [Bordeaux], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-CRLCC Eugène Marquis (CRLCC), CHRU Brest - Service de médecine nucléaire (CHU - BREST - Med Nucléaire), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Recherches en cancérologie, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunomedics, Inc., Université de Rennes (UR)-Hôpital Pontchaillou, CHU Bordeaux [Bordeaux]-Institut Bergonié [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-CRLCC Eugène Marquis (CRLCC), Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux]-Centre Régional de Lutte Contre le Cancer Institut Bergonié (Bordeaux), Centre Hospitalier Bretagne Atlantique [Vannes], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], CHU Cochin [AP-HP], and Institut Bergonié - CRLCC Bordeaux
Subjects: 0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Population, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Chemoimmunotherapy, immune system diseases, Internal medicine, hemic and lymphatic diseases, medicine, education, ComputingMilieux_MISCELLANEOUS, education.field_of_study, business.industry, Induction chemotherapy, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, medicine.disease, 3. Good health, Surgery, Transplantation, 030104 developmental biology, 030220 oncology & carcinogenesis, Radioimmunotherapy, Rituximab, business, Epratuzumab, Diffuse large B-cell lymphoma, medicine.drug
Abstract: BACKGROUND: Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 (90)Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma. METHODS: We did a prospective, single-group, phase 2 trial at 28 hospitals in France, with patients recruited from 17 hospitals. Eligible patients were aged 60-80 years with bulky stage 2-3 or stage 3-4 CD20-positive diffuse large B-cell lymphoma, previously untreated, and not eligible for transplantation. Patients received six cycles of R-CHOP (rituximab [375 mg/m(2)], cyclophosphamide [750 mg/m(2)], doxorubicin [50 mg/m(2)], and vincristine [1·4 mg/m(2), up to 2 mg] all on day 1, and prednisone [40 mg/m(2)] daily for 5 days), administered every 14 days. 6-8 weeks after R-CHOP, responders received two doses of 15 mCi/m(2) (555 MBq/m(2)) (90)Y-epratuzumab tetraxetan administered 1 week apart. The primary endpoint was 2 year event-free survival in all registered eligible patients who received at least 1 day of study treatment; the safety analysis was done in the same population. This trial is registered with ClinicalTrials.gov, number NCT00906841. FINDINGS: Between Oct 22, 2008, and Dec 16, 2010, we recruited 75 patients, of whom four (5%) were excluded after central pathology review; hence, 71 (95%) patients were included in the analysis. All patients started induction treatment; 57 (80%) received radioimmunotherapy. With a median follow-up of 37 months (IQR 30-44), the estimated 2 year event-free survival was 75% (95% CI 63-84). Radioimmunotherapy toxicity consisted of grade 3-4 thrombocytopenia in 48 (84%) of 57 patients and neutropenia in 45 (79%) of 57 patients. One patient developed myelodysplastic syndrome 28 months after receiving radioimmunotherapy and one patient developed acute myeloid leukaemia 5 months after receiving radioimmunotherapy. INTERPRETATION: Fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan might be appropriate for response consolidation after induction chemotherapy in older patients with advanced diffuse large B-cell lymphoma, but further comparative studies are needed. FUNDING: Immunomedics, Amgen, Canceropole Grand Ouest, the GOELAMS/LYSA group and the French National Agency for Research (Investissements d'Avenir).
Published: 2017
Full Text: View/download PDF

16. Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method

Author: Vincent Jaouen, Baptiste Laurent, Mathieu Hatt, Dimitris Visvikis, Hadi Fayad, Catherine Cheze Le Rest, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut National de la Santé et de la Recherche Médicale (INSERM)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-IMT Atlantique (IMT Atlantique), Université européenne de Bretagne - European University of Brittany (UEB)-Université de Brest (UBO)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), and Hatt, Mathieu
Subjects: Lung Neoplasms, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, [INFO.INFO-IM] Computer Science [cs]/Medical Imaging, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Imaging phantom, 030218 nuclear medicine & medical imaging, Sphericity, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Correlation, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, [INFO.INFO-LG]Computer Science [cs]/Machine Learning [cs.LG], Fluorodeoxyglucose F18, Carcinoma, Non-Small-Cell Lung, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, Radiology, Nuclear Medicine and imaging, Segmentation, PET functional volumes, Mathematics, Active contour model, Image segmentation, Radiomics, business.industry, Hazard ratio, Bayes Theorem, General Medicine, [INFO.INFO-LG] Computer Science [cs]/Machine Learning [cs.LG], Prognosis, Tumor Burden, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [INFO.INFO-TI] Computer Science [cs]/Image Processing [eess.IV], Positron-Emission Tomography, 030220 oncology & carcinogenesis, [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], Nuclear medicine, business, Volume (compression)
Abstract: Sphericity has been proposed as a parameter for characterizing PET tumour volumes, with complementary prognostic value with respect to SUV and volume in both head and neck cancer and lung cancer. The objective of the present study was to investigate its dependency on tumour delineation and the resulting impact on its prognostic value. Five segmentation methods were considered: two thresholds (40% and 50% of SUVmax), ant colony optimization, fuzzy locally adaptive Bayesian (FLAB), and gradient-aided region-based active contour. The accuracy of each method in extracting sphericity was evaluated using a dataset of 176 simulated, phantom and clinical PET images of tumours with associated ground truth. The prognostic value of sphericity and its complementary value with respect to volume for each segmentation method was evaluated in a cohort of 87 patients with stage II/III lung cancer. Volume and associated sphericity values were dependent on the segmentation method. The correlation between segmentation accuracy and sphericity error was moderate (|ρ| from 0.24 to 0.57). The accuracy in measuring sphericity was not dependent on volume (|ρ
Published: 2017
Full Text: View/download PDF

17. Immuno-PET for Clinical Theranostic Approaches

Author: Bailly, Clément, Cléry, Pierre-François, Faivre-Chauvet, Alain, Bourgeois, Mickael, Guérard, François, Haddad, Ferid, Barbet, Jacques, Chérel, Michel, Kraeber-Bodéré, Françoise, Carlier, Thomas, Bodet-Milin, Caroline, Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Département de Médecine Nucléaire (NANTES - Médecine Nucléaire), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Accélérateur pour la Recherche en Radiochimie et Oncologie [Nantes Atlantique] (GIP ARRONAX), Université de Nantes (UN)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain]-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Laboratoire de physique subatomique et des technologies associées (SUBATECH), Université de Nantes - Faculté des Sciences et des Techniques, Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), Université de Nantes (UN)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), Bernardo, Elizabeth, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, and Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID
Subjects: Antibodies, Monoclonal, [SDV.CAN]Life Sciences [q-bio]/Cancer, Review, [PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex], molecular imaging, lcsh:Chemistry, lcsh:Biology (General), lcsh:QD1-999, [SDV.CAN] Life Sciences [q-bio]/Cancer, Neoplasms, Positron-Emission Tomography, antibody, immuno-PET, Animals, Humans, Radiopharmaceuticals, lcsh:QH301-705.5, ComputingMilieux_MISCELLANEOUS
Abstract: International audience; Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals.
Published: 2017
Full Text: View/download PDF

18. Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III

Author: Mathieu Hatt, Florent Tixier, R. Perdrisot, Catherine Cheze Le Rest, Marie-Charlotte Desseroit, Mohamed Majdoub, Rémy Guillevin, Dimitris Visvikis, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Data Analysis and Computations Through Imaging Modeling-Mathématiques, Imagerie, Santé (DACTIM-MIS), Laboratoire de Mathématiques et Applications (LMA-Poitiers), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), This work has received a French government support granted to theCominLabs excellence laboratory and managed by the National Research Agency inthe 'Investing for the Future' program under reference ANR-10-LABX-07-01, andsupport from the city of Brest., ANR-10-LABX-0007,COMIN Labs,Digital Communication and Information Sciences for the Future Internet(2010), ANR-10-LABX-07-01,labex Cominlabs,Laboratoire d'excellence CominLabs(2013), Université européenne de Bretagne - European University of Brittany (UEB)-Université de Brest (UBO)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hatt, Mathieu, and Digital Communication and Information Sciences for the Future Internet - - COMIN Labs2010 - ANR-10-LABX-0007 - LABX - VALID
Subjects: Adult, Male, medicine.medical_specialty, Lung Neoplasms, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Article, 030218 nuclear medicine & medical imaging, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Positron Emission Tomography Computed Tomography, medicine, Humans, Radiology, Nuclear Medicine and imaging, Stage (cooking), Lung cancer, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Fluorodeoxyglucose, PET-CT, Reproducibility, medicine.diagnostic_test, business.industry, General Medicine, Middle Aged, Nomogram, medicine.disease, Tumor Burden, 3. Good health, Nomograms, 030220 oncology & carcinogenesis, Female, Tomography, Radiology, Nuclear medicine, business, Emission computed tomography, medicine.drug
Abstract: International audience; Our goal was to develop a nomogram by exploiting intratumour heterogeneity on CT and PET images from routine (18)F-FDG PET/CT acquisitions to identify patients with the poorest prognosis. This retrospective study included 116 patients with NSCLC stage I, II or III and with staging (18)F-FDG PET/CT imaging. Primary tumour volumes were delineated using the FLAB algorithm and 3D Slicer™ on PET and CT images, respectively. PET and CT heterogeneities were quantified using texture analysis. The reproducibility of the CT features was assessed on a separate test-retest dataset. The stratification power of the PET/CT features was evaluated using the Kaplan-Meier method and the log-rank test. The best standard metric (functional volume) was combined with the least redundant and most prognostic PET/CT heterogeneity features to build the nomogram. PET entropy and CT zone percentage had the highest complementary values with clinical stage and functional volume. The nomogram improved stratification amongst patients with stage II and III disease, allowing identification of patients with the poorest prognosis (clinical stage III, large tumour volume, high PET heterogeneity and low CT heterogeneity). Intratumour heterogeneity quantified using textural features on both CT and PET images from routine staging (18)F-FDG PET/CT acquisitions can be used to create a nomogram with higher stratification power than staging alone.
Published: 2016
Full Text: View/download PDF

19. Reliability of PET/CT shape and heterogeneity features in functional and morphological components of Non-Small Cell Lung Cancer tumors: a repeatability analysis in a prospective multi-center cohort

Author: Desseroit, Marie-Charlotte, Tixier, Florent, Weber, Wolfgang, Siegel, Barry A, Rest, Catherine Cheze Le, Visvikis, Dimitris, Hatt, Mathieu, CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Memorial Sloane Kettering Cancer Center [New York], Mallinckrodt Institute of Radiology and the Siteman Cancer Center, Washington University School of Medicine, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), M-C Desseroit’s PhD is partly funded by Brest Métropôle Océane. F. Tixier is funded by the association 'Sport and Collection', CHRU Poitiers. This work has received a French government support granted to the CominLabs excellence laboratory and managed by the National Research Agency in the 'Investing for the Future' program under reference ANR-10-LABX-07-01. With the support of the National Institute of Cancer (INCa project #C14020NS). The original trials from which the images used in this study were obtained were supported by the U.S. National Cancer Institute through grants U01-CA079778 and U01-CA080098 and by Merck & Co., Inc., Université européenne de Bretagne - European University of Brittany (UEB)-Université de Brest (UBO)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), and Hatt, Mathieu
Subjects: FOS: Computer and information sciences, [INFO.INFO-TS] Computer Science [cs]/Signal and Image Processing, PET/CT, Computer Vision and Pattern Recognition (cs.CV), Computer Science - Computer Vision and Pattern Recognition, [INFO.INFO-IM] Computer Science [cs]/Medical Imaging, FOS: Physical sciences, [INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Physics - Medical Physics, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, [INFO.INFO-CV] Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV], [SDV.CAN] Life Sciences [q-bio]/Cancer, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, radiomics, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Medical Physics (physics.med-ph), repeatability, texture analysis
Abstract: Purpose: The main purpose of this study was to assess the reliability of shape and heterogeneity features in both Positron Emission Tomography (PET) and low-dose Computed Tomography (CT) components of PET/CT. A secondary objective was to investigate the impact of image quantization.Material and methods: A Health Insurance Portability and Accountability Act -compliant secondary analysis of deidentified prospectively acquired PET/CT test-retest datasets of 74 patients from multi-center Merck and ACRIN trials was performed. Metabolically active volumes were automatically delineated on PET with Fuzzy Locally Adaptive Bayesian algorithm. 3DSlicerTM was used to semi-automatically delineate the anatomical volumes on low-dose CT components. Two quantization methods were considered: a quantization into a set number of bins (quantizationB) and an alternative quantization with bins of fixed width (quantizationW). Four shape descriptors, ten first-order metrics and 26 textural features were computed. Bland-Altman analysis was used to quantify repeatability. Features were subsequently categorized as very reliable, reliable, moderately reliable and poorly reliable with respect to the corresponding volume variability. Results: Repeatability was highly variable amongst features. Numerous metrics were identified as poorly or moderately reliable. Others were (very) reliable in both modalities, and in all categories (shape, 1st-, 2nd- and 3rd-order metrics). Image quantization played a major role in the features repeatability. Features were more reliable in PET with quantizationB, whereas quantizationW showed better results in CT.Conclusion: The test-retest repeatability of shape and heterogeneity features in PET and low-dose CT varied greatly amongst metrics. The level of repeatability also depended strongly on the quantization step, with different optimal choices for each modality. The repeatability of PET and low-dose CT features should be carefully taken into account when selecting metrics to build multiparametric models., Journal of Nuclear Medicine, Society of Nuclear Medicine, 2016
Published: 2016

20. Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results

Author: Habiba Mesbah, Sophie Laffont, Philippe Porée, Yan Rolland, Etienne Garin, Bruno Clément, Laurence Lenoir, Julien Edeline, Jean-Luc Raoul, Eveline Boucher, Microenvironnement et remodelage, Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC)-CRLCC Eugène Marquis (CRLCC), Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), Département d'Imagerie Médicale [Rennes], Université de Rennes (UR)-Hôpital Pontchaillou, Département d'oncologie médicale [Rennes], Département d'informatique médicale, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), CRLCC Eugène Marquis (CRLCC)-CRLCC Eugène Marquis (CRLCC)-Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Département de médecine nucléaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: Male, Multimodal Imaging, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, MESH: Liver Neoplasms, Yttrium Radioisotopes, MESH: Yttrium Radioisotopes, MESH: Carcinoma, Hepatocellular, Radiation treatment planning, 90Y, MESH: Treatment Outcome, MESH: Aged, education.field_of_study, dosimetry, medicine.diagnostic_test, Liver Neoplasms, hepatocellular carcinoma, Embolization, Therapeutic, Microspheres, MESH: Glass, 3. Good health, Portal vein thrombosis, Treatment Outcome, Positron emission tomography, MESH: Survival Analysis, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, Radiology, radioembolization, medicine.medical_specialty, Carcinoma, Hepatocellular, Population, MESH: Microspheres, MESH: Positron-Emission Tomography and Computed Tomography, 03 medical and health sciences, Carcinoma, medicine, MESH: Technetium Tc 99m Aggregated Albumin, Humans, Dosimetry, Radiology, Nuclear Medicine and imaging, Radiometry, education, Technetium Tc 99m Aggregated Albumin, Survival analysis, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Radiometry, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Survival Analysis, MESH: Male, MESH: Embolization, Therapeutic, Positron-Emission Tomography, Glass, Tomography, X-Ray Computed, business, Nuclear medicine, MESH: Female
Abstract: International audience; UNLABELLED: Radioembolization of liver cancers using (90)Y-loaded microspheres is experiencing more widespread use. However, few data are available concerning the doses delivered to the tumors and the healthy liver. This retrospective study was conducted to calculate the tumor dosimetry (planned tumor dose [T(plan) D]) and nontumor dosimetry in patients treated by (90)Y-loaded glass microspheres and determine whether tumor dosimetry could predict response and survival. METHODS: Thirty-six patients with hepatocellular carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-loaded glass microspheres. The T(plan) D and the dose delivered to the injected healthy liver were calculated using a quantitative analysis of the (99m)Tc-macroaggregated albumin ((99m)Tc-MAA) SPECT/CT exam. Responses were assessed after 3 mo, using the criteria of the European Association for the Study of the Liver. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier tests. RESULTS: The response rate was 69% for the overall population and 75% for the PVT patients. The dose delivered to the tumor was the only parameter associated with response with multivariate analysis (P = 0.019). A threshold T(plan) D value of 205 Gy was predictive of response, with a sensitivity of 100% and an accuracy of 91%. Quantitative (99m)Tc-MAA SPECT/CT allowed us to increase the injected activity for 4 patients with large lesions. PFS was only 5.2 mo and OS 9 mo when using a T(plan) D of less than 205 Gy versus 14 mo (P = 0.0003) and 18 mo (P = 0.0322), respectively, with a T(plan) D of 205 Gy or more. CONCLUSION: Quantitative (99m)Tc-MAA SPECT/CT is predictive of response, PFS, and OS. Dosimetry based on (99m)Tc-MAA SPECT/CT can be used for the selection of patients and for an adaptation of treatment planning, especially in selected patients (particularly in the case of large tumors). These results also confirm the efficacy and safety of (90)Y-loaded microspheres in treating HCC, even in the presence of PVT (and especially when (99m)Tc-MAA uptake is seen inside the PVT).
Published: 2012
Full Text: View/download PDF

21. Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer

Author: Cédric eMathieu, Ludovic eFerrer, Thomas eCarlier, Mathilde eColombié, Daniela eRusu, Françoise eKraeber-Bodéré, Loic eCampion, Caroline eRousseau, Département de Médecine Nucléaire [Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Département de Médecine Nucléaire [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Physique Médicale [Saint-Herblain], Département de Statistiques [Saint Herblain], This work has been supported in part by grants from the French National Agency for Research called 'Investissements d’Avenir' Labex IRON no. ANR-11-LABX-0018-01., ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), Bernardo, Elizabeth, and Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID
Subjects: Pathology, medicine.medical_specialty, dynamic curves, Partial volume, [SDV.CAN]Life Sciences [q-bio]/Cancer, Malignancy, 18F-choline, Prostate cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Prostate, medicine, Lymph node, Original Research, early acquisition, PET-CT, lcsh:R5-920, Receiver operating characteristic, business.industry, General Medicine, medicine.disease, prostate cancer, medicine.anatomical_structure, pathological status, Medicine, Lymph, business, Nuclear medicine, lcsh:Medicine (General)
Abstract: Introduction: Dynamic image acquisition with 18F-Choline (FCH) PET/CT in prostate cancer is mostly used to overcome the bladder repletion which could obstruct the loco-regional analysis. The aim was to analyze early dynamic FCH acquisitions to define pelvic lymph node or prostate pathological status. Material and methods: Retrospective analysis was performed on 39 patients for initial staging (n=18), or after initial treatment (n=21). Patients underwent ten-minute dynamic acquisitions centered on the pelvis, after injection of 3-4 MBq/kg of FCH. Whole body images were acquired about one hour after injection using a PET/CT GE Discovery LS (GE-LS) or Siemens Biograph mCT (mCT). Maximum and mean SUV according to time were measured on nodal and prostatic lesions. SUVmean was corrected for partial volume effect (PVEC) with suitable recovery coefficients. The status of each lesion was based on histological results or patient follow-up (>6 months). A Mann-Whitney test and ANOVA were used to compare mean and receiver operating characteristic curve analysis. Results: The median PSA was 8.46 ng/mL and the median Gleason score was 3+4. Ninety-two lesions (43 lymph nodes and 49 prostate lesions) were analyzed, including 63 malignant lesions. In early dynamic acquisitions, the maximum and mean SUV were significantly higher, respectively on mCT and GE-LS, in malignant versus benign lesions (p
Published: 2015
Full Text: View/download PDF

22. Radiomics in PET/CT: More Than Meets the Eye?

Author: Florent Tixier, Dimitris Visvikis, Catherine Cheze Le Rest, Mathieu Hatt, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hatt, Mathieu, and Université européenne de Bretagne - European University of Brittany (UEB)-Université de Brest (UBO)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Subjects: PET-CT, business.industry, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Radiomics, Fluorodeoxyglucose F18, X ray computed, Positron Emission Tomography Computed Tomography, 030220 oncology & carcinogenesis, Medicine, Radiology, Nuclear Medicine and imaging, Tomography, Tomography, X-Ray Computed, business, Nuclear medicine, ComputingMilieux_MISCELLANEOUS, Positron Emission Tomography-Computed Tomography
Abstract: International audience
Published: 2016
Full Text: View/download PDF

23. Rare duplication of the CDC73 gene and atypical hyperparathyroidism‐jaw tumor syndrome: A case report and review of the literature

Author: Guilhaume Garrigues, Marie Batisse‐Lignier, Nancy Uhrhammer, Maud Privat, Flora Ponelle‐Chachuat, Antony Kelly, Mathilde Gay‐Bellile, Sandrine Viala, Yannick Bidet, Yves‐Jean Bignon, Mathias Cavaillé, Centre Jean Perrin, Département d'oncogénétique, Département de Médecine nucléaire, Centre Jean PERRIN, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
Subjects: rare duplication, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, adenomyosis, Genetics, HPT-JT syndrome, [SDV.CAN]Life Sciences [q-bio]/Cancer, CDC73, Molecular Biology, Genetics (clinical)
Abstract: International audience; BackgroundHyperparathyroidism jaw-tumor syndrome (HPT-JT) is the rarest familial cause of primary hyperparathyroidism, with an incidence
Published: 2023
Full Text: View/download PDF

24. Quantification of intra-tumor 18F-FDG PET tracer uptake heterogeneity through textural features analysis: Which minimum functional tumor volume to consider?

Author: Hatt, Mathieu, TIXIER , Florent, Majdoub, Mohamed, Cheze-Le Rest, Catherine, Pradier, Olivier, Hustinx, Roland, Visvikis, Dimitris, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Centre Hospitalier Universitaire de Poitiers - Département de médecine nucléaire (Centre Hospitalier Universitaire de Poitiers) (CHRU Poitiers - Département de médecine nucléaire), CHRU Brest, Service de radiothérapie (CHU Brest -Radiothérapie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Médecine nucléaire (Centre Hospitalier universitaire de Liège) (CHU LIEGE), Département Image et Traitement Information (ITI), and Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)
Subjects: [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine
Abstract: International audience; Intra-tumor uptake heterogeneity in PET has been associated with patient outcome in several cancer models. Amongst the proposed methods for its quantification, textural features (TF) analysis provides several local and regional parameters. One of the issues associated with the use of TF analysis is its applicability may depend on a minimum metabolically active tumor volume (MATV), that has been claimed to be 45 cm3, based on entropy (1). The objective of this work was to verify this assertion for the entire range of TF.Several patients' cohorts in different cancer models (head&neck, lung, esophageal, and cervix) were pooled to create a database of 308 tumors with FDG PET images. A subset of 6 local and 5 regional TF were investigated according to their reproducibility and robustness assessed in previous studies. The correlation with MATV was investigated with spearman rank coefficients (rho) and a threshold of rho=0.80 was considered to differentiate features with potential complementary information with respect to MATV based on previous studies.Range of MATV was 3-415 cm3 (mean=35, median=21). Correlation between MATV and TF (table 1) ranged from 0.31 to 0.98. No significant differences were found in different cancer models. Even ≤10 cm3, 4 local and 3 regional features provided complementary information with respect to volume (rho≤0.80). Correlations decreased with increasing MATV and most features fell below the threshold (even entropy) except intensity variability and size-zone variability.Our results suggest that heterogeneity quantification through TF may potentially provide complementary information even for volumes below 45 cm3, although it is reduced with smaller volumes.
Published: 2014

25. FDG PET derived quantitative heterogeneity features reflect gene expression profiles in head and neck cancer

Author: Tixier, Florent, Cheze-Le Rest, Catherine, CHEZEAUD, Stéphanie, KEY, Stéphane, Simon, Brigitte, POTARD, Gael, Valette, Gérald, Hatt, Mathieu, Corcos, Laurent, Visvikis, Dimitris, Télécom Bretagne (devenu IMT Atlantique), Ex-Bibliothèque, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Centre Hospitalier Universitaire de Poitiers - Département de médecine nucléaire (Centre Hospitalier Universitaire de Poitiers) (CHRU Poitiers - Département de médecine nucléaire), Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) (GGB), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Département Image et Traitement Information (ITI), and Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)
Subjects: [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, [SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing
Abstract: International audience; FDG PET has a well-established diagnostic role in oncology and has been shown as a powerful tool for patient treatment management. Quantifying tumor heterogeneity in PET images was shown to be of added value since such characteristics are supposed to be related to tumor underlying physiological processes. The aim of this study was thus to study the relationship between FDG PET derived tumor features and gene expression profiles provided by microarray analysis. 25 patients with head and neck cancer treated by radio-chemotherapy were prospectively recruited. Patients underwent an FDG PET scan at diagnosis and a biopsy on both healthy and tumor tissues for transcriptomic analysis. 15 PET image derived features, including functional tumor volume, SUVs and heterogeneity quantification by textural analysis, were considered. Transcriptomic analysis was carried out with Agilent 4x44k microarrays. A module network algorithm was used to identify groups of genes related to the PET features. Finally, a functional annotation was carried out to establish a correspondence between PET features and biological pathways. Microarrays allowed the identification of 1177 genes differentially expressed between tumor and healthy tissues with a fold change above 2 (p
Published: 2014

26. Endogenous Ethanol and Triglyceride Production by Gut Pichia kudriavzevii, Candida albicans and Candida glabrata Yeasts in Non-Alcoholic Steatohepatitis

Author: Mbaye, Babacar, Borentain, Patrick, Magdy Wasfy, Reham, Alou, Maryam Tidjani, Armstrong, Nicholas, Mottola, Giovanna, Meddeb, Line, Ranque, Stéphane, Gérolami, René, Million, Matthieu, Raoult, Didier, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Médecine Nucléaire [AP-HM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)- Hôpital Nord [CHU - APHM], Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Assistance Publique - Hôpitaux de Marseille (APHM), ANR-15-CE36-0004,MHT,Analyse des facteurs associés à la non-observance a hygiène des mains par enregistrement continue des gestes d'hygiène en situation de soins avec un traceur par radiofréquence associé à un enregistreur de tache au lit du patient.(2015), and ANR-10-IAHU-0003,Méditerranée Infection,I.H.U. Méditerranée Infection(2010)
Subjects: nonalcoholic fatty liver disease, gut microbiota, [SDV]Life Sciences [q-bio], yeast, microbial culturomics, metabolic syndrome, fructose, auto-brewery syndrome, gut mycobiome, metabolic-associated fatty liver disease, ethanol, fungi, nonalcoholic steatohepatitis, Pichia kudriavzevii, Candida
Abstract: International audience; Nonalcoholic steatohepatitis (NASH) increases with fructose consumption and metabolic syndrome and has been recently linked with endogenous ethanol production, notably by high alcohol-producing Klebsiella pneumoniae (HiAlc Kpn). Candida yeasts are the main causes of auto-brewery syndromes but have been neglected in NASH. Here, the fecal ethanol and microbial content of 10 cases and 10 controls were compared. Ethanol was measured by gas chromatography-mass spectrometry. Species identification was performed by MALDI-TOF MS, and triglyceride production was assessed by a colorimetric enzymatic assay. The fecal ethanol concentration was four times higher in patients with NASH (median [interquartile range]: 0.13 [0.05–1.43] vs. 0.034 [0.008–0.57], p = 0.037). Yeasts were isolated from almost all cases but not from controls (9/10 vs. 0/10, p = 0.0001). Pichia kudriavzevii was the most frequent (four patients), while Candida glabrata, Candida albicans, and Galactomyces geotrichum were identified in two cases each. The concentration of ethanol produced by yeasts was 10 times higher than that produced by bacteria (median, 3.36 [0.49–5.60] vs. 0.32 [0.009–0.43], p = 0.0029). Using a 10% D-fructose restricted medium, we showed that NASH-associated yeasts transformed fructose in ethanol. Unexpectedly, yeasts isolated from NASH patients produced a substantial amount of triglycerides. Pichia kudriavzevii strains produced the maximal ethanol and triglyceride levels in vitro. Our preliminary human descriptive and in vitro experimental results suggest that yeasts have been neglected. In addition to K. pneumoniae, gut Pichia and Candida yeasts could be linked with NASH pathophysiology in a species- and strain-specific manner through fructose-dependent endogenous alcohol and triglyceride production.
Published: 2022
Full Text: View/download PDF

27. Local Recurrence Risk Score to Predict Relapse after Stereotactic Body Radiation Therapy for Lung Tumors

Author: Isabelle Pougnet, Paul Habert, Sarkis Delcourt, Mohamed Boucekine, Stephanie Wong, Audrey Zacchariotto, Xavier Muracciole, Jean-Yves Gaubert, Laetitia Padovani, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire d'Imagerie Interventionnelle Expérimentale (LIIE), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Européen de Recherche en Imagerie médicale (CERIMED), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-École Centrale de Marseille (ECM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Centre National de la Recherche Scientifique (CNRS), Service d’imagerie médicale [Hôpital Nord - APHM], Hôpital Nord [CHU - APHM], Département de Médecine Nucléaire [AP-HM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)- Hôpital Nord [CHU - APHM], Support Unit for Clinical Research and Economic Evaluation, Assistance Publique-Hôpitaux de Marseille, Marseille 13385, and Département de Radiologie [Hôpital de la Timone - APHM]
Subjects: X-ray, stereotactic radiations, follow up studies, [SDV.CAN]Life Sciences [q-bio]/Cancer, General Medicine, non-small-cell lung carcinomas, CT scanner, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background: After stereotactic body radiation therapy (SBRT) for lung tumors, follow-up CT scans remain a pitfall. The early detection of local relapse is essential to propose a new treatment. We aim to create a local recurrence predictive score using pre- and post-therapeutic imaging criteria and test it on a validation cohort. Methods: Between February 2011 and July 2016, lung tumors treated by SBRT with available pretreatment fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) and follow-up CT scans were retrospectively analyzed. The risk factors associated with relapse were identified by univariate logistic regression on a train cohort. The score was created using these factors, merging clinical and imaging criteria associated with local relapse, and then tested on an independent validation cohort. Overall and local relapse-free survival at 1 and 3 years were recorded. Results: Twenty-eight patients were included in the train cohort and ten in the derivation cohort (male 74%, median age 70 ± 12 years). Five variables significantly associated with local recurrence (female gender; sequential enlargement; craniocaudal growing; bulging margins; standardized uptake value (SUVmax > 5.5)) were combined to create the score on five points. With the threshold >2.5/5, the sensitivity and specificity of the score on the validation cohort were 100% and 88%, respectively. Overall survival and local relapse-free survival at 1 and 3 years were 89% and 42%, and 89% and 63%, respectively. Conclusion: The local recurrence risk score created has high sensitivity (100%) and specificity (88%), upon independent validation cohort, to detect local relapse. This score is easy to use in daily clinical practice.
Published: 2022
Full Text: View/download PDF

28. Potassium iodide (KI) prophylaxis in the case of a nuclear accident: A new marketing authorization in France

Author: Marc Benderitter, Francois Caire-Maurisier, Caroline Crambes, Thierry Pourcher, Jean-Charles Martin, Jacques Darcourt, Maâmar Souidi, Pôle Santé Environnement - Direction Santé (IRSN/PSE-SANTE), Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Pharmacie Centrale des Armées (PCA), Direction des Approvisionnements en produits de Santé des Armées, Fleury-les-Aubrais, 45404, France (PCA), Transporteurs et Imagerie, Radiothérapie en Oncologie et Mécanismes biologiques des Altérations du Tissu Osseux (TIRO-MATOs - UMR E4320), Service Hospitalier Frédéric Joliot (SHFJ), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-UMR E4320 (TIRO-MATOs), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Médecine Nucléaire [Nice] (CHU-Nice), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA)-UNICANCER-Université Côte d'Azur (UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice), Laboratoire de radiotoxicologie et radiobiologie expérimentale (IRSN/PSE-SANTE/SESANE/LRTOX), Service de recherche sur les effets biologiques et Sanitaires des rayonnements ionisants (IRSN/PSE-SANTE/SESANE), Institut de Radioprotection et de Sûreté Nucléaire (IRSN)-Institut de Radioprotection et de Sûreté Nucléaire (IRSN), and ANR-11-RSNR-0019,PRIODAC,Prophylaxie répétée par l'iode stable et contre-mesures innovantes en situation accidentelle(2011)
Subjects: Thyroid, Global and Planetary Change, Potassium iodide, Potassium iodide Thyroid Nuclear accident Iodine thyroid blocking, Environmental Chemistry, Iodine thyroid blocking, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Environmental Science (miscellaneous), Nuclear accident
Abstract: International audience; Prophylaxis by “KI 65 mg, breakable tablet” is a pharmacological countermeasure of radiological protection adapted for the prevention of thyroid cancer after exposure to radioactive iodine. A first modification of the marketing authorization of “KI 65 mg, breakable tablet” for repeated prophylaxis for adults and children above 12 years old was obtained in France in 2020. At this point in time it is recommended to exclude the repeated intake of “KI- 65 mg, breakable tablet” by pregnant and breastfeeding women and children below 12 years old, who should consequently be subjected to a priority evacuation from the contaminated zone. Regulatory toxicology studies are underway in order to support an upcoming proposal of modification of the marketing authorization of “KI- 65 mg, breakable tablet” for repeated prophylaxis for pregnant women and children below 12 years old.
Published: 2022
Full Text: View/download PDF

29. PET Uptake Heterogeneity Quantification for Therapy Response in Oncology: Dependency on Image Pre-processing and Tumor Delineation

Author: Hatt, Mathieu, Tixier, Florent, Cheze-Le Rest, Catherine, VISVIKIS, Dimitris, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Université de Brest (UBO), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Direction Scientifique (DS), and Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)
Subjects: ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2013

30. Impact of Delineation and Partial Volume Effects Correction on PET Uptake Heterogeneity Quantification Through Textural Features Analysis for Therapy Response in Oncology

Author: Hatt, Mathieu, Tixier, Florent, Cheze-Le Rest, Catherine, VISVIKIS, Dimitris, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Direction Scientifique (DS), and Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)
Abstract: International audience; Purpose: characterization of intra tumoral tracer uptake heterogeneity in PET imaging for response to therapy assessment applications in oncology has been investigated in several recent studies. The use of textural features to quantify this heterogeneity has shown promising results for response to therapy prediction. However, there is no study available yet regarding the potential impact of pre-processing steps on the resulting heterogeneity quantification. The goal of this work was therefore to assess the dependency of heterogeneity parameters obtained through textural features on delineation and partial volume effects (PVE) correction (PVC). Methods: fifty patients with esophageal cancer were retrospectively analyzed. PVC of each FDG PET image was performed using iterative deconvolution with wavelet-based denoising. The tumors were delineated using fixed (FT) and adaptive thresholding (AT), and the fuzzy locally adaptive Bayesian (FLAB) algorithm. From the resulting delineations, uptake heterogeneity was quantified using the following features, selected for their reproducibility and robustness: entropy (E), homogeneity (H), dissimilarity (D), intensity variability (IV), size-zone variability (SZV) and high intensity emphasis (HIE). The results obtained with FLAB (the most accurate) on the non-corrected image were chosen as reference. Variability with respect to this reference depending on delineation or PVC was assessed using Bland-Altman analysis. Impact on the associated predictive value regarding the identification on non-responders was assessed by comparing areas under the receiver operating characteristic curves. Results: heterogeneity parameters were more dependent on delineation than PVC. The most sensitive parameters were IV and SZV (90-100% variability). The most independent were E, H and HIE (10-50%). The impact on the corresponding predictive value was not significant, except for SZV and HIE after deconvolution (p
Published: 2013

31. Robustness of intra-tumor 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in esophageal carcinoma

Author: Hatt, Mathieu, Tixier, Florent, Cheze-Le Rest, Catherine, Pradier, Olivier, VISVIKIS, Dimitris, Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), and Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Abstract: International audience; Purpose: Intratumour uptake heterogeneity in PET quantified in terms of textural features for response to therapy has been investigated in several studies, including assessment of their robustness for reconstruction and physiological reproducibility. However, there has been no thorough assessment of the potential impact of preprocessing steps on the resulting quantification and its predictive value. The goal of this work was to assess the robustness of PET heterogeneity in textural features for delineation of functional volumes and partial volume correction (PVC. Methods: This retrospective analysis included 50 patients with oesophageal cancer. PVC of each PET image was performed. Tumour volumes were determined using fixed and adaptive thresholding, and the fuzzy locally adaptive Bayesian algorithm, and heterogeneity was quantified using local and regional textural features. Differences in the absolute values of the image-derived parameters considered were assessed using Bland-Altman analysis. The impact on their predictive value for the identification of patient nonresponders was assessed by comparing areas under the receiver operating characteristic curves. Results: Heterogeneity parameters were more dependent on delineation than on PVC. The parameters most sensitive to delineation and PVC were regional ones (intensity variability and size zone variability), whereas local parameters such as entropy and homogeneity were the most robust. Despite the large differences in absolute values obtained from different delineation methods or after PVC, these differences did not necessarily translate into a significant impact on their predictive value. Conclusion: Parameters such as entropy, homogeneity, dissimilarity (for local heterogeneity characterization) and zone percentage (for regional characterization) should be preferred. This selection is based on a demonstrated high differentiation power in terms of predicting response, as well as a significant robustness with respect to the delineation method used and the partial volume effects.
Published: 2013

32. Qualitative versus quantitative assessment of intra-tumor FDG heterogeneity for assessing patient outcome in NSCLC

Author: VALLA, Clémence, Tixier, Florent, Hatt, Mathieu, PERDRISOT, Remy, VISVIKIS, Dimitris, Cheze-Le Rest, Catherine, CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), Direction Scientifique (DS), and Institut Mines-Télécom [Paris] (IMT)-Télécom Bretagne
Abstract: International audience; Objectives: Intra-tumor FDG distribution heterogeneity has been recently proposed as a PET image derived index for assessing and/or predicting therapy response and patient survival considering multiple cancer models. Such an evaluation has been almost exclusively based on the use of textural features allowing to quantitatively assess heterogeneity at different spatial scales. The objective of this study is to compare a qualitative assessment of FDG uptake distribution heterogeneity with a quantitative analysis based on textural features in patients with non-small cell lung cancer (NSCLC), considering both response to therapy and progression free survival. Methods: 95 NSCLC patients were included in this retrospective study. All patients underwent a PET/CT scan as part of the initial staging procedure. Response to treatment was assessed using the RESIST criteria and a minimum of 2 years follow up was available for all patients. FDG intra-tumor heterogeneity was assessed visually using a three levels scale by two nuclear medicine physicians. On the other hand textural features were used to quantitatively assess local, regional and global tumor uptake heterogeneity. The predictive value of all these heterogeneity parameters was evaluated using Kruskal-Wallis tests and receiver operating characteristics analysis. The prognostic value of each parameter for overall survival was investigated using Kaplan-Meier and Cox regression models for univariate and multivariate analyses, respectively. Results: Both visual and quantitative FDG tumor uptake heterogeneity correlated significantly with patient response to therapy. Visual heterogeneity assessment better correlated with regional quantitative heterogeneity indices. There was a high inter-observer agreement on the evaluation of visual heterogeneity. Conclusions: Intra-tumor heterogeneity assessed qualitatively and quantitatively allows predicting response to therapy and patient outcome and may be useful in stratifying patient management in NSCLC.
Published: 2013

33. Proliferative 18F-FLT PET tumor volumes characterization for prediction of locoregional recurrence and disease-free survival in head and neck cancer

Author: Majdoub, Mohamed, VISVIKIS, Dimitris, TEXIER, Florent, HOEBEN, Bianca, VISSER, Eric, Cheze-Le Rest, Catherine, Hatt, Mathieu, Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), Direction Scientifique (DS), Institut Mines-Télécom [Paris] (IMT)-Télécom Bretagne, Department of Radiation Oncology, Radboud University Medical Center [Nijmegen], CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), and Centre hospitalier universitaire de Poitiers (CHU Poitiers)
Abstract: International audience; Objectives: Local recurrence in head and neck cancer after chemoradiotherapy is associated with poor outcome. The ability to predict such local recurrence could be of clinical value in order to identify patients that may benefit from intensified treatment and/or more frequent follow-up. The objective of this study was to investigate the value of proliferative tumor volumes characterization from 18F-FLT PET images for prognosis of disease free survival (DFS) and prediction of locoregional recurrence. Methods: 45 head and neck cancer patients treated with (chemo)radiotherapy who underwent a pre-treatment 18F-FLT PET were retrospectively included. Proliferative tumor volumes were characterized after automatic delineation with the Fuzzy Locally Adaptive Bayesian algorithm using image analysis providing parameters such as SUV measurements, as well as 3D shape descriptors and textural features. DFS prognostic value was assessed using Kaplan-Meier analysis. Locoregional recurrence predictive value was assessed using a random forest (RF) classifier that was subsequently validated using the leave-one-out strategy. Results: Accuracy of the RF classifier in predicting locoregional recurrence using a subset of the most optimal features was 86 %. Kaplan-Meier analysis demonstrated that textural features and proliferative volume are prognostic factors of DFS, larger, more heterogeneous proliferative volume being associated with shorter DFS. Conclusions: Our results suggest that 3D shape descriptors and textural features characterizing shape and heterogeneity of head and neck tumors proliferative volumes in baseline 18F-FLT images may help identify subgroups of patients at increased risk of developing a locoregional recurrence after head and neck cancer (chemo)radiotherapy.
Published: 2013

34. 18F-FDG PET image-derived tumor characterization to improve prediction of response to neoadjuvant chemotherapy on locally advanced breast cancer

Author: Hatt, Mathieu, Groheux, David, Martineau, Antoine, Espie, Marc, HINDIE, Elif, Giacchetti, Sylvie, VISVIKIS, Dimitris, Cheze-Le Rest, Catherine, Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), and Centre hospitalier universitaire de Poitiers (CHU Poitiers)
Abstract: International audience; Objectives: Early prediction of no response to neoadjuvant chemotherapy (NAC) in breast cancer may help in identifying patients that would benefit from alternative therapeutic strategies. The objective of this study was to assess the potential predictive value of tumor characterization from 18F-FDG PET images including metabolically active tumor volume (MATV) and uptake heterogeneity characterization using texture analysis. Methods: 89 patients were included who underwent scans at baseline (PET1) and before the 3rd cycle of NAC (PET2). Pathological response was assessed after surgery using the Sataloff scale. Several image-derived parameters were extracted from delineated MATVs, including SUV max, peak and mean; total lesion glycolysis (TLG); local/regional textural features. The predictive value of these parameters at PET1 or PET2, and their evolution between PET1 and PET2 ({Delta}param, %) was assessed through receiver operating characteristic (ROC) area under the curve (AUC) analysis. Results: There were 45 responders and 44 nonresponders. There was no response differentiation using PET1 absolute values only for any of the parameters considered (AUCs
Published: 2013

35. Predictive value of tumor uptake heterogeneity spatial patterns in sequential 18F-FDG PET for rectal cancer radio-chemotherapy response monitoring

Author: Hatt, Mathieu, Tixier, Florent, Cheze-Le Rest, Catherine, VAN STIPHOUT, R, Lammering, Guido, Lambin, Philippe, VISVIKIS, Dimitris, Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Maastricht Radiation Oncology Clinic (MAASTRO), Maastricht University [Maastricht], Direction Scientifique (DS), and Institut Mines-Télécom [Paris] (IMT)-Télécom Bretagne
Abstract: International audience; Objectives: 18F-FDG PET image-derived indices such as textural features have been recently introduced to provide characterization of uptake heterogeneity. The objective of this retrospective study was to assess their predictive value on sequential scans during treatment for rectal cancer. Methods: 28 patients were included; all underwent 3 scans, at baseline (PET1), 1 week (PET2), and 2 weeks (PET3) into treatment. Tumor response grade (TRG) was assessed by histopathology after surgery, and patients were classified as responders (TRG 1-2) and non-responders (TRG 3-5). Several local and regional uptake heterogeneity parameters (homogeneity, entropy) were extracted. The predictive value of these parameters at PET1, as well as their evolution at PET2 and PET3 was evaluated using receiver operating characteristics (ROC) area under the curves (AUC), and were compared to standard parameters (functional volume, SUV). Results: Prediction of no response using baseline PET1 values was not accurate (AUC values from 0.58 for homogeneity to 0.75 for SUVmean). Although results were not improved by considering differences with PET2 parameters, the use of PET3 derived values led to AUCs varying from 0.79 ({Delta}SUVmean, {Delta}TLG) to 0.88 for {Delta}homogeneity (94% sensitivity, 83% specificity). Combining 2 parameters (for example SUVmean and homogeneity) at PET1 or PET2 through logistic regression led to improved AUCs of 0.80 and 0.95 respectively. SUVmax consistently showed a lower predictive value. Conclusions: Characterization of the tumor uptake spatial heterogeneity may provide complementary information of added predictive value within the context of radio-chemotherapy response monitoring using sequential 18F-FDG PET scans in the management of rectal cancer. Combination of several parameters to derive more accurate predictive models is feasible however it will require training and validation in larger cohorts, which will be the focus of future studies.
Published: 2013

36. Caractérisation de tumeur à partir d'images TEP au 18F FDG pour améliorer la prédiction de la réponse à la chimiothérapie néoadjuvante du cancer du sein

Author: Hatt, Mathieu, Groheux, David, Martineau, Antoine, Espie, Marc, Hindie, Elif, Giacchetti, Sylvie, de Roquancourt, A, Visvikis, Dimitris, Cheze-Le Rest, Catherine, Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Brest (UBO), Service de médecine nucléaire [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Direction Scientifique (DS), Institut Mines-Télécom [Paris] (IMT)-Télécom Bretagne, CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), and Télécom Bretagne (devenu IMT Atlantique), Ex-Bibliothèque
Subjects: ComputingMilieux_MISCELLANEOUS
Abstract: National audience
Published: 2013

37. Intratumor or heterogeneity characterization in 18F-FDG PET images predicts overall survival and recurrence in head and neck cancer

Author: Tixier, Florent, Hatt, Mathieu, Cheze-Le Rest, Catherine, Corcos, Laurent, VISVIKIS, Dimitris, Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), and Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Subjects: ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2013

38. Improving the accuracy of 18F-FDG PET for early prediction of response to neoadjuvant chemotherapy in breast cancer

Author: Hatt, Mathieu, Groheux, David, Martineau, Antoine, Espie, Marc, HINDIE, Elif, Giacchetti, Sylvie, DE ROQUANCOURT, A, VISVIKIS, Dimitris, Cheze-Le Rest, Catherine, Télécom Bretagne (devenu IMT Atlantique), Ex-Bibliothèque, Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine nucléaire [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Direction Scientifique (DS), Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire de Traitement de l'Information Medicale (LaTIM), and Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT)
Subjects: ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2013

39. Decrease in the cortex/striatum metabolic ratio on [18F]-FDG PET: a biomarker of autoimmune encephalitis

Author: Frison, Eric, PROUST-LIMA, Cecile, Mangin, Jean-Francois, Habert, Marie-Odile, Bombois, Stephanie, Ousset, Pierre-Jean, Pasquier, Florence, Hanon, Olivier, Paquet, Claire, Gabelle, Audrey, Ceccaldi, Mathieu, Annweiler, Cédric, Krolak-Salmon, Pierre, Béjot, Yannick, Belin, Catherine, Wallon, David, Sauvee, Mathilde, Beaufils, Emilie, Bourdel-Marchasson, Isabelle, Jalenques, Isabelle, Chupin, Marie, Chêne, Geneviève, Dufouil, Carole, De Leiris, Nicolas, Ruel, Berangère, Vervandier, Jean, Boucraut, José, Grimaldi, Stephan, Horowitz, Tatiana, Pelletier, Jean, Fluchere, Frederique, Campion, Jacques-Yves, Kaphan, Elsa, Guedj, Eric, Service de médecine nucléaire [Marseille], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Imagerie MOléculaire pour applications THéranostiques personnalisées (IMOTHEP), Institut FRESNEL (FRESNEL), Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Européen de Recherche en Imagerie médicale (CERIMED), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-École Centrale de Marseille (ECM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Centre National de la Recherche Scientifique (CNRS), Université Grenoble Alpes (UGA), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Médecine Nucléaire [AP-HM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)- Hôpital Nord [CHU - APHM], Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), and Guedj, Eric
Subjects: 18 F-FDG PET/CT, medicine.medical_specialty, Multivariate analysis, Striatum, Statistical parametric mapping, Gastroenterology, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, statistical parametric mapping, 0302 clinical medicine, Internal medicine, Cortex (anatomy), medicine, Radiology, Nuclear Medicine and imaging, Autoimmune encephalitis, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Receiver operating characteristic, business.industry, General Medicine, medicine.disease, MCI, medicine.anatomical_structure, inflammation, Encephalitis, biomarker, Biomarker (medicine), business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery
Abstract: The aim of this [18F]-FDG PET study was to determine the diagnostic value of the cortex/striatum metabolic ratio in a large cohort of patients suffering from autoimmune encephalitis (AE) and to search for correlations with the course of the disease. We retrospectively collected clinical and paraclinical data of patients with AE, including brain 18F-FDG PET/CT. Whole-brain statistical analysis was performed using SPM8 software after activity parametrization to the striatum in comparison to healthy subjects. The discriminative performance of this metabolic ratio was evaluated in patients with AE using receiver operating characteristic curves against 44 healthy subjects and a control group of 688 patients with MCI. Relationship between cortex/striatum metabolic ratios and clinical/paraclinical data was assessed using univariate and multivariate analysis in patients with AE. Fifty-six patients with AE were included. In comparison to healthy subjects, voxel-based statistical analysis identified one large cluster (p-cluster
Published: 2021
Full Text: View/download PDF

40. Novel voxel-wise textural feature analysis for intra-tumor heterogeneity characterization in PET imaging

Author: Le Pogam, Adrien, Tixier, Florent, Hatt, Mathieu, Cheze-Le Rest, Catherine, VISVIKIS, Dimitris, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Université de Brest (UBO), CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), and Centre hospitalier universitaire de Poitiers (CHU Poitiers)
Subjects: ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2012

41. Comparaison IRM de diffusion corps entier et TEP/TDM au 18FDG dans le diagnostic de myélome symptomatique. [Comparison between whole-body diffusion MRI and 18FDG PET/CT in the diagnosis of symptomatic myeloma]

Author: Brillet, E., Decaux, Olivier, Bernard, A.-M., Devillers, Anne, Lamy De La Chapelle, T., Bertaud-Gounot, V., Saint-Jalmes, Hervé, Guillin, A., Garin, Etienne, Duvauferrier, Regis, Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], CHU Pontchaillou [Rennes], Modélisation Conceptuelle des Connaissances Biomédicales, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), Service d'Hématologie, Immunologie et de Thérapie Cellulaire (HITC), Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microenvironnement et remodelage, CHU Pontchaillou [Rennes]-CHU Pontchaillou [Rennes]-Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC)-CRLCC Eugène Marquis (CRLCC)-Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Département de médecine nucléaire [Rennes], and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Biomarqueurs, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Myélome multiple, [SDV.IB]Life Sciences [q-bio]/Bioengineering, IRM de diffusion, IRM corps entier, TEP/TDM, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing
Abstract: International audience; Introduction Notre travail a pour objectif d'évaluer la restriction en IRM de diffusion corps entier (DWMRI) comme marqueur diagnostique du myélome en comparaison à la TEP/TDM au 18FDG. Patients et méthode De novembre 2008 à mai 2010, nous avons exploré par DWMRI et par TEP/TDM au 18FDG, 19 patients atteints de myélome ou porteurs de Monoclonal Gammapathy of Undetermined Significance (MGUS). Les patients ont été classés par le clinicien référent comme myélome symptomatique ou non, suivant les critères internationaux en huit myélomes non symptomatiques et 11 myélomes symptomatiques. Nous avons, sur cette base, étudié la sensibilité et la spécificité des deux méthodes d'imagerie en retenant la présence ou l'absence d'une infiltration diffuse (ID), de lésions focales (LF), ou des deux paramètres (LF+ID), dans les deux modalités d'imagerie. La concordance des deux techniques a été testée pour chaque patient à l'aide d'un test du kappa pondéré. Résultats La sensibilité et la spécificité des lésions focales et de l'infiltration diffuse ne sont pas différentes entre les deux modalités, avec des performances diagnostiques supérieures pour les LF (Se=100 % et Sp=75 % en DWMRI et Se=91 % et Sp=75 % pour la TEP/TDM au 18FDG). En combinant les deux paramètres, la TEP/TDM au 18FDG semble plus spécifique, mais la sensibilité est comparable (Se=100 % en DWMRI et Se=100 % en TEP/TDM au 18FDG ; Sp=37 % en DWMRI et Sp=62 % en TEP/TDM au 18FDG). La concordance entre les deux techniques est meilleure pour les LF que pour l'ID (kappa pondéré=0,6 pour les LF, 0,5 pour LF+ID et 0,16 pour l'ID). Conclusion Les performances diagnostiques de la DWMRI et de la TEP/TDM au 18FDG sont proches, mais la concordance entre les deux techniques n'est pas parfaite. Des études futures seront nécessaires afin de comprendre ces discordances.
Published: 2012
Full Text: View/download PDF

42. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

Author: Sandrine Boyault, Thomas Bachelot, Alain Puisieux, Christine Lasset, Claudine Navarro, Isabelle Treilleux, Youenn Drouet, Eric Tabone, Qing Wang, Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Equipe de prévention et épidémiologie génétique, Centre Léon Bérard [Lyon], Biologie Fonctionnelle, Insectes et Interactions (BF2I), Institut National de la Recherche Agronomique (INRA)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA), Luzhou Medical college, Department of spinal surgery, Eq 11, Oncogénèse et progression tumorale, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Département de Médecine Nucléaire, Eq 09, Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Département de Biopathologie, Centre Léon Bérard [Lyon]-Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Eq 02, Institut Universitaire de France (IUF), Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Département de Médecine Nucléaire, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Département de Biopathologie, Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.)-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Genomique Fonctionnelle des Tumeurs Solides, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ) -IFR105-Université Paris Diderot - Paris 7 ( UPD7 ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Département de Médecine Nucléaire, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Département de Biopathologie, Centre Léon Bérard [Lyon]-Hospices Civils de Lyon ( HCL ) -Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ) -Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ), Biologie Fonctionnelle, Insectes et Interactions ( BF2I ), Institut National de la Recherche Agronomique ( INRA ) -Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université de Lyon-Institut National des Sciences Appliquées ( INSA ), Institut Universitaire de France ( IUF ), Ministère de l'Éducation nationale, de l’Enseignement supérieur et de la Recherche ( M.E.N.E.S.R. ) -Ministère de l'Éducation nationale, de l’Enseignement supérieur et de la Recherche ( M.E.N.E.S.R. ) -Centre de Recherche en Cancérologie de Lyon ( CRCL ), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )
Subjects: MESH: Signal Transduction, Receptors, Steroid, Cancer Research, DNA Mutational Analysis, MESH : Aged, AKT1, Kaplan-Meier Estimate, MESH : PTEN Phosphohydrolase, MESH : Breast Neoplasms, Gene mutation, MESH: Cadherins, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, CDH1, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, MESH: Carcinoma, Lobular, MESH : Female, MESH: DNA Mutational Analysis, MESH: Tumor Suppressor Protein p53, MESH: Genetic Association Studies, Genetics, MESH: Aged, 0303 health sciences, MESH: Middle Aged, Carcinoma, Ductal, Breast, MESH : Carcinoma, Lobular, Middle Aged, MESH : Adult, Cadherins, 3. Good health, MESH : Proto-Oncogene Proteins c-akt, Oncology, 030220 oncology & carcinogenesis, Female, MESH : Cadherins, Signal Transduction, Adult, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : DNA Mutational Analysis, Biology, MESH: PTEN Phosphohydrolase, MESH : Kaplan-Meier Estimate, 03 medical and health sciences, Breast cancer, Antigens, CD, medicine, Humans, PTEN, MESH : Middle Aged, Gene, Genetic Association Studies, PI3K/AKT/mTOR pathway, MESH: Kaplan-Meier Estimate, Aged, 030304 developmental biology, MESH : Signal Transduction, MESH: Humans, MESH: Proto-Oncogene Proteins c-akt, MESH : Humans, PTEN Phosphohydrolase, MESH : Carcinoma, Ductal, Breast, MESH : Phosphatidylinositol 3-Kinases, MESH: Adult, MESH : Genetic Association Studies, medicine.disease, MESH: Carcinoma, Ductal, Breast, Carcinoma, Lobular, MESH : Tumor Suppressor Protein p53, MESH: Phosphatidylinositol 3-Kinases, biology.protein, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-akt, MESH : Receptors, Steroid, MESH: Female, MESH: Breast Neoplasms, MESH: Receptors, Steroid
Abstract: International audience; Understanding how cancer genes are mutated in individual tumors is an important issue with potential clinical and therapeutic impact. This is especially relevant with recently developed targeted therapies since mutated genes can be targets and/or predictors. However, to date, gene mutation profiling in individual tumors is still underexplored. Breast cancer is composed of various subtypes. We presumed that this heterogeneity reflected the involvement of different molecular mechanisms including gene mutations that affect defined signaling pathways. Unlike the majority of published mutational studies, this study was aimed to draw a mutation profile in individual tumors by screening a panel of cancer genes in the same tumor. Thus, five genes frequently mutated in breast cancers: TP53, PIK3CA, PTEN, CDH1, and AKT1 were screened in each of 120 human primary breast tumors. Mutations in at least one of these genes were found in 62.5% of the tumors, of which the majority carried a single-gene mutation. Interestingly, a substantial proportion of tumors carried mutations either in TP53 or in genes of the PI3K pathway (PIK3CA or PTEN or AKT1). These two distinct mutation patterns were significantly associated to hormone receptor expression but independent of HER2 status.
Published: 2012
Full Text: View/download PDF

43. MRI data driven partial volume effects correction in PET imaging using 3D local multi resolution analysis

Author: Le Pogam, Adrien, Hatt, Mathieu, Lamare, Frédéric, Fernandez, Philippe, Cheze-Le Rest, Catherine, VISVIKIS, Dimitris, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Service de médecine nucléaire [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), and Centre hospitalier universitaire de Poitiers (CHU Poitiers)
Abstract: International audience; PET partial volume effects (PVE) resulting from the limited resolution of PET scanners is still a quantitative issue that PET/MRI scanners do not solve by themselves. A recently proposed voxel-based locally adaptive 3D multi-resolution PVE correction based on the mutual analysis of wavelet decompositions was applied on 12 clinical 18F-FLT PET/T1 MRI images of glial tumors, and compared to a PET only voxel-wise iterative deconvolution approach. Quantitative and qualitative results demonstrated the interest of exploiting PET/MRI information with higher uptake increases (19±8% vs. 11±7%, p=0.02), as well as more convincing visual restoration of details within tumors with respect to deconvolution of the PET uptake only. Further studies are now required to demonstrate the accuracy of this restoration with histopathological validation of the uptake in tumors.
Published: 2012

44. Delayed [18F]-FDG PET Imaging Increases Diagnostic Performance and Reproducibility to Differentiate Recurrence of Brain Metastases From Radionecrosis

Author: Otman, Hosameldin, Farce, Julien, Meneret, Pierre, Palard-Novello, Xavier, Le Reste, Pierre-Jean, Lecouillard, Isabelle, Vauleon, Elodie, Chanchou, Marion, Carsin Nicol, Beatrice, Bertaux, Marc, Devillers, Anne, Mariano-Goulart, Denis, Cachin, Florent, Girard, Antoine, Le Jeune, Florence, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurochirurgie [Rennes] = Neurosurgery [Rennes], CHU Pontchaillou [Rennes], Département d'oncologie médicale [Rennes], Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Service de Neuroradiologie [Rennes], Hôpital Foch [Suresnes], Service de médecine nucléaire [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), and MORNET, Dominique
Subjects: Brain Neoplasms, [SDV]Life Sciences [q-bio], Reproducibility of Results, radiation necrosis, General Medicine, radiation therapy, [SDV] Life Sciences [q-bio], Necrosis, PET, Fluorodeoxyglucose F18, Positron-Emission Tomography, brain metastases, Humans, Radiology, Nuclear Medicine and imaging, Radiopharmaceuticals, Radiation Injuries, ComputingMilieux_MISCELLANEOUS, [18F]-FDG PET, Retrospective Studies
Abstract: International audience; Purpose Differentiating brain metastasis recurrence from radiation necrosis can be challenging during MRI follow-up after stereotactic radiotherapy. [F-18]-FDG is the most available PET tracer, but standard images performed 30 to 60 minutes postinjection provide insufficient accuracy. We compared the diagnostic performance and interobserver agreement of [F-18]-FDG PET with delayed images (4-5 hours postinjection) with the ones provided by standard and dual-time-point imaging. Methods Consecutive patients referred for brain [F-18]-FDG PET after inconclusive MRI were retrospectively included between 2015 and 2020 in 3 centers. Two independent nuclear medicine physicians interpreted standard (visually), delayed (visually), and dual-time-point (semiquantitatively) images, respectively. Adjudication was applied in case of discrepancy. The final diagnosis was confirmed histologically or after 6 months of MRI follow-up. Areas under the receiver operating characteristic curves were pairwise compared. Results Forty-eight lesions from 46 patients were analyzed. Primary tumors were mostly located in the lungs (57%) and breast (23%). The median delay between radiotherapy and PET was 15.7 months. The final diagnosis was tumor recurrence in 24 of 48 lesions (50%), with histological confirmation in 19 of 48 lesions (40%). Delayed images provided a larger area under the receiver operating characteristic curve (0.88; 95% confidence interval [CI], 0.75-0.95) than both standard (0.69; 95% CI, 0.54-0.81; P = 0.0014) and dual-time-point imaging (0.77; 95% CI, 0.63-0.88; P = 0.045), respectively. Interobserver agreement was almost perfect with delayed images (kappa = 0.83), whereas it was moderate with both standard (kappa = 0.48) and dual-time-point images (kappa = 0.61). Conclusions [F-18]-FDG PET with delayed images is an accurate and reliable alternative to differentiate metastasis recurrence from radiation necrosis in case of inconclusive MRI after brain stereotactic radiotherapy.
Published: 2022
Full Text: View/download PDF

45. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

Author: Yan Rolland, Anne Devillers, Ludovic Le Dortz, Florence Le Jeune, Thierry Lamy, Sophie de Guibert, Haïfa Bahri, Marie-Luce Barge, Roch Houot, Etienne Garin, Sahar Bayat, Marc Cuggia, Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'hématologie clinique, Université de Rennes (UR)-Hôpital Pontchaillou, Laboratoire d'Informatique Médicale (LIM), Université de Rennes (UR), Microenvironnement et cancer (MiCa), Microenvironnement et remodelage, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC)-CRLCC Eugène Marquis (CRLCC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Département de médecine nucléaire [Rennes]
Subjects: Male, MESH: Subtraction Technique, Treatment outcome, Follicular lymphoma, Computed tomography, 030218 nuclear medicine & medical imaging, MESH: Lymphoma, Follicular, 0302 clinical medicine, MESH: Fluorodeoxyglucose F18, Lymphoma, Follicular, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, MESH: Immunologic Factors, General Medicine, Middle Aged, Prognosis, MESH: Positron-Emission Tomography, 3. Good health, MESH: Reproducibility of Results, Treatment Outcome, Positron emission tomography, 030220 oncology & carcinogenesis, Fdg pet ct, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Tomography, Radiology, MESH: Tomography, X-Ray Computed, MESH: Radiopharmaceuticals, medicine.medical_specialty, Therapeutic response, Sensitivity and Specificity, MESH: Prognosis, 03 medical and health sciences, Fluorodeoxyglucose F18, medicine, Humans, Immunologic Factors, Radiology, Nuclear Medicine and imaging, Aged, MESH: Humans, business.industry, Reproducibility of Results, medicine.disease, MESH: Sensitivity and Specificity, MESH: Male, Lymphoma, 18F-FDG, PET, Positron-Emission Tomography, Subtraction Technique, Radiopharmaceuticals, Nuclear medicine, business, Tomography, X-Ray Computed, MESH: Female
Abstract: International audience; PURPOSE: The aim of this study was to assess the usefulness of positron emission tomography/computed tomography in staging, prognosis evaluation and restaging of patients with follicular lymphoma. METHODS: A retrospective study was performed on 45 patients with untreated biopsy-proven follicular lymphoma who underwent 18F-fluorodeoxyglucose PET/CT (FDG PET/CT) and CT before and after chemoimmunotherapy induction treatment (rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone). RESULTS: PET/CT detected more nodal (+51%) and extranodal (+89%) lesions than CT. PET/CT modified Ann Arbor staging in eight patients (18%). Five patients (11%) initially considered as being early stage (I/II) were eventually treated as advanced stage (III/IV). In this study, an initial PET/CT prognostic score was significantly more accurate than the Follicular Lymphoma International Prognostic Index score in identifying patients with poor prognosis (i.e. patients with incomplete therapeutic response or early relapse). The accuracy of PET/CT for therapeutic response assessment was higher than that of CT (0.97 vs 0.64), especially due to its ability to identify inactive residual masses. In addition, post-treatment PET/CT was able to predict patients' outcomes. The median progression-free survival was 48 months in the PET/CT-negative group as compared with 17.2 months for the group with residual uptake (p
Published: 2010
Full Text: View/download PDF

46. Whole-body MR imaging in suspected physical child abuse: comparison with skeletal survey and bone scintigraphy findings from the PEDIMA prospective multicentre study

Author: Proisy, Maïa, Vivier, Pierre-Hugues, Morel, Baptiste, Bruneau, Bertrand, Sembely-Taveau, Catherine, Vacheresse, Solène, Devillers, Anne, Lecloirec, Joseph, Bodet-Milin, Caroline, Dubois, Marine, Hamonic, Stéphanie, Bajeux, Emma, Ganivet, Anne, Adamsbaum, Catherine, Treguier, Catherine, Abalea, Lydie, Croly-Labourdette, Séverine, Dam Hieu, Phong, Dobrzynski, Murielle, Fenoll, Bertrand, Forlodou, Pierre, Le Bot, Christiane, Lefranc, Jérémie, Lesoeur, Mélanie, Mériot, Philippe, Peudenier, Sylviane, Querello, Solène, Salaun, Pierre Yves, Olivier, Pierre, Martrille, Laurent, Borsa-Dorion, Anne, Galloy, Marie-Agnès, Mainard-Simard, Laurence, Raffo, Emmanuel, Cavare-Vigneron, Sylvie, Claudon, Michel, Klein, Olivier, Schmitt, Emmanuelle, Le Tacon, Serge, Morel, Olivier, Lapp, Lucie, Bodere-Kraeber, Françoise, Milin, Caroline, Fleury, Juliette, Geffroy, Loïc, Hamel, Sophie, Lefrancois, Thomas, Longis, Marie-Pierre, Mayrargue, Emmanuelle, Picherot, Georges, Quéré, Marie-Pierre, Rozé, Jean-Christophe, Vabres, Nathalie, Bouvet, Renaud, Le Gueut, Mariannick, Riffaud, Laurent, Balençon, Martine, Bétrémieux, Pierre, Chapuis, Madeleine, Chasle, Véronique, Dabadie, Alain, Damaj, Léna, Darnault, Pierre, de La Brière, François, Delahaye, Séverine, Duvauferrier, Regis, Farges, Céline, Fraisse, Bernard, Gaillot, Théophile, Gardin, Maryse, Gauvrit, Cécile, Guitteny, Marie-Aline, Marleix, Sylvette, Napuri, Silvia, Roussey, Michel, Rozel, Céline, Tirel, Olivier, Vignaud, Catherine, Violas, Philippe, Wodey, Eric, Pierre, Marion, Pladys, Patrick, Abu-Amara, Saad, Bachy, Bruno, Brasseur-Daudruy, Marie, Dacher, Jean-Nicolas, Delmon, Pascal, Lechevallier-Amara, Joël, Lerebours, Bénédicte, Leroux, Julien, Proust, Francois, Rigal, Sophie, Baulieu, Jean-Louis, Venel, Yann, Elodie, Carpentier, Chantepie, Alain, Chantreuil, Julie, Come, Mathieu, de Courtivron, Benoit, Labarthe, François, Marot, Yves, Pepin-Donat, Myriam, Sirinelli, Dominique, Travers, Nadine, Urvois-Grange, Annie, O'Byrne, Patrick, Listrat, Antoine, Barge-Galern, Marie-Luce, Le Cloirec, Joseph, Vera, Pierre, Kone-Paut, I., Deiva, Kumaran, Chaumet-Riffaud, Philippe, Grimon, Gilles, Archambaud, Frederique, Zenkhri, Ferielle, Galeotti, Caroline, Sevette-Béchard, Nancy, Prodhomme, Olivier, Leconte, Céline, Haquet, Armelle, Bourdon, Aurélie, Sainmont, Mélanie, De-Pontual, Loic, Sellier, Nicolas, Trieu, Thanh-Van, de Labriolle-Vaylet, Claire, Département de Radiologie [Rennes], Université de Rennes (UR), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire [Rennes], Département de Radiologie [AP-HP Hôpital Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), PEDIMA study research group: Lydie Abalea, Séverine Croly-Labourdette, Phong Dam Hieu, Murielle Dobrzynski, Bertrand Fenoll, Pierre Forlodou, Christiane Le Bot, Jérémie Lefranc, Mélanie Lesoeur, Philippe Meriot, Sylviane Peudenier, Solène Querello, Pierre-Yves Salaun, Pierre Olivier, Laurent Martrille, Anne Borsa-Dorion, Marie-Agnès Galloy, Laurence Mainard-Simard, Emmanuel Raffo, Sylvie Cavare-Vigneron, Michel Claudon, Olivier Klein, Emmanuelle Schmitt, Serge Le Tacon, Olivier Morel, Lucie Lapp, Françoise Bodéré-Kraeber, Caroline Milin, Juliette Fleury, Loïc Geffroy, Sophie Hamel, Antoine Hamel, Thomas Lefrançois, Marie-Pierre Longis, Emmanuelle Mayrargue, Georges Picherot, Marie-Pierre Quéré, Jean-Christophe Rozé, Nathalie Vabres, Renaud Bouvet, Mariannick Le Gueut, Laurent Riffaud, Martine Balençon, Pierre Bétrémieux, Madeleine Chapuis, Véronique Chasle, Alain Dabadie, Léna Damaj, Pierre Darnault, François De La Brière, Séverine Delahaye, Régis Duvauferrier, Céline Farges, Bernard Fraisse, Théophile Gaillot, Maryse Gardin, Cécile Gauvrit, Marie-Aline Guitteny, Sylvette Marleix, Silvia Napuri, Michel Roussey, Céline Rozel, Olivier Tirel, Catherine Tréguier, Catherine Vignaud, Philippe Violas, Eric Wodey, Marion Pierre, Patrick Pladys, Saad Abu-Amara, Bruno Bachy, Marie Brasseur-Daudruy, Jean-Nicolas Dacher, Pascal Delmon, Joël Lechevallier Amara, Bénédicte Lerebours, Julien Leroux, François Proust, Sophie Rigal, Pierre-Hugues Vivier, Jean-Louis Baulieu, Yann Venel, Elodie Carpentier, Alain Chantepie, Julie Chantreuil, Mathieu Come, Benoît De Courtivron, François Labarthe, Yves Marot, Myriam Pepin Donat, Dominique Sirinelli, Nadine Travers, Annie Urvois-Grangé, Patrick O'Byrne, Antoine Listrat, Marie-Luce Barge-Galerne, Joseph Le Cloirec, Pierre Vera, Isabelle Koné-Paut, Kumaran Deiva, Philippe Chaumet-Riffaud, Gilles Grimon, Frédérique Archambaud, Ferielle Zenkhri, Caroline Galeotti, Nancy Sevette Béchard, Olivier Prodhomme, Céline Leconte, Armelle Haquet, Aurélie Bourdon, Mélanie Sainmont, Loïc De Pontual, Nicolas Sellier, Thanh-Van Trieu, Claire De Labriolle-Vaylet., Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), and DACHER, Jean Nicolas
Subjects: Child abuse, medicine.medical_specialty, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Skeletal survey, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Sensitivity and Specificity, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, 0302 clinical medicine, parasitic diseases, medicine, Humans, Whole Body Imaging, Radiology, Nuclear Medicine and imaging, Child Abuse, Prospective Studies, Child, Radionuclide Imaging, Neuroradiology, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, medicine.diagnostic_test, business.industry, Infant, Interventional radiology, Magnetic resonance imaging, General Medicine, Magnetic Resonance Imaging, Occult, Confidence interval, 3. Good health, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, Physical Abuse, Bone scintigraphy, 030220 oncology & carcinogenesis, Radiology, Tomography, X-Ray Computed, business
Abstract: International audience; Objectives: To assess the contribution of whole-body magnetic resonance imaging (WBMRI) and bone scintigraphy (BS) in addition to skeletal survey (SS) in detecting traumatic bone lesions and soft-tissue injuries in suspected child abuse.Methods: In this prospective, multicentre, diagnostic accuracy study, children less than 3 years of age with suspected physical abuse were recruited. Each child underwent SS, BS and WBMRI. A blinded first review was performed in consensus by five paediatric radiologists and three nuclear medicine physicians. A second review investigated discrepancies reported between the modalities using a consensus result of all modalities as the reference standard. We calculated the sensitivity, specificity and corresponding 95% confidence interval for each imaging modality (SS, WBMRI and BS) and for the combinations [SS + WBMRI] and [SS + BS].Results: One hundred seventy children were included of which sixty-four had at least one lesion. In total, 146 lesions were included. The sensitivity and specificity of each examination were, respectively, as follows: 88.4% [95% CI, 82.0-93.1] and 99.7% [95% CI, 99.5-99.8] for the SS, 69.9% [95% CI, 61.7-77.2] and 99.5% [95% CI, 99.2-99.7] for WBMRI and 54.8% [95% CI, 46.4-63.0] and 99.7% [95% CI, 99.5-99.9] for BS. Sensitivity and specificity were, respectively, 95.9% [95% CI, 91.3-98.5] and 99.2% [95% CI, 98.9-99.4] for the combination SS + WBMRI and 95.2% [95% CI, 90.4-98.1] and 99.4% [95% CI, 99.2-99.6] for the combination SS + BS, with no statistically significant difference between them.Conclusion: SS was the most sensitive independent imaging modality; however, the additional combination of either WBMRI or BS examinations offered an increased accuracy.Key points: • SS in suspected infant abuse was the most sensitive independent imaging modality in this study, especially for detecting metaphyseal and rib lesions, and remains essential for evaluation. • The combination of either SS + BS or SS + WBMRI provides greater accuracy in diagnosing occult and equivocal bone injuries in the difficult setting of child abuse. • WBMRI is a free-radiation technique that allows additional diagnosis of soft-tissue and visceral injuries.
Published: 2021
Full Text: View/download PDF

47. Monte Carlo simulation of digital photon counting PET

Author: Joey Labour, David Sarrut, Julien Salvadori, Laetitia Imbert, Freddy Odille, Jean-Noël Badel, Pierre-Yves Marie, Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Nancyclotep- Experimental Imaging Platform = Plate-forme d'imagerie moléculaire, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Université de Lorraine (UL), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de médecine nucléaire, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), and Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Subjects: lcsh:Medical physics. Medical radiology. Nuclear medicine, Computer science, lcsh:R895-920, Monte Carlo method, Biomedical Engineering, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Radiology, Nuclear Medicine and imaging, Sensitivity (control systems), Instrumentation, Monte Carlo simulation, Original Research, Radiation, NEMA, Lines of response, Detector, Experimental data, Scatter fraction, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, Photon counting, PET, 030220 oncology & carcinogenesis, Algorithm, Energy (signal processing), Digital photon counting
Abstract: A GATE Monte Carlo model of the Philips Vereos digital photon counting PET imaging system using silicon photo-multiplier detectors was proposed. It was evaluated against experimental data in accordance with NEMA guidelines. Comparisons were performed using listmode data in order to remain independent of image reconstruction algorithms. An original line of response-based method is proposed to estimate intrinsic spatial resolution without reconstruction. Four sets of experiments were performed: (1) count rates and scatter fraction, (2) energy and timing resolutions, (3) sensitivity, and (4) intrinsic spatial resolution. Experimental and simulated data were found to be in good agreement, with overall differences lower than 10% for activity concentrations used in most standard clinical applications. Illustrative image reconstructions were provided. In conclusion, the proposed Monte Carlo model was validated and can be used for numerous studies such as optimizing acquisition parameters or reconstruction algorithms.
Published: 2020
Full Text: View/download PDF

48. 18F-FDG PET/CT-Based Prognostic Survival Model After Surgery for Head and Neck Cancer

Author: Gwenaelle Creff, Franck Jegoux, Xavier Palard, Adrien Depeursinge, Ronan Abgral, Remi Marianowski, Jean-Christophe Leclere, Thomas Eugene, Olivier Malard, Renaud De Crevoisier, Anne Devillers, Joel Castelli, Jonchère, Laurent, CHU Pontchaillou [Rennes], Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), Centre Eugène Marquis (CRLCC), Haute Ecole Spécialisée de Suisse Occidentale (HES-SO), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), LTSI, INSERM, U1099 (Rennes, France), and Cancer Institute (Rennes, France)
Subjects: [SDV.IB] Life Sciences [q-bio]/Bioengineering, overall sur-vival, 030218 nuclear medicine & medical imaging, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, PET, distant metastasis, 030220 oncology & carcinogenesis, Radiology, Nuclear Medicine and imaging, head and neck cancer, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Clinical Investigation, prognosis, CT
Abstract: International audience; The aims of this multicenter study were to identify clinical and preop-erative PET/CT parameters predicting overall survival (OS) and distant metastasis???free survival (DMFS) in a cohort of head and neck squa-mous cell carcinoma patients treated with surgery, to generate a prog-nostic model of OS and DMFS, and to validate this prognostic model with an independent cohort. Methods: A total of 382 consecutive patients with head and neck squamous cell carcinoma, divided into training (n = 318) and validation (n = 64) cohorts, were retrospectively included. The following PET/CT parameters were analyzed: clinical parameters, SUVmax, SUVmean, metabolic tumor volume (MTV), total lesion glycolysis, and distance parameters for the primary tumor and lymph nodes defined by 2 segmentation methods (relative SUVmax threshold and absolute SUV threshold). Cox analyses were performed for OS and DMFS in the training cohort. The concordance index (c-index) was used to identify highly prognostic parameters. These prognostic parameters were externally tested in the validation cohort. Results: In multivariable analysis, the significant parameters for OS were T stage and nodal MTV, with a c-index of 0.64 (P < 0.001). For DMFS, the significant parameters were T stage, nodal MTV, and maxi-mal tumor???node distance, with a c-index of 0.76 (P < 0.001). These combinations of parameters were externally validated, with c-indices of 0.63 (P < 0.001) and 0.71 (P < 0.001) for OS and DMFS, respec-tively. Conclusion: The nodal MTV associated with the maximal tumor???node distance was significantly correlated with the risk of DMFS. Moreover, this parameter, in addition to clinical parameters, was associated with a higher risk of death. These prognostic factors may be used to tailor individualized treatment. Superscript/Subscript Available
Published: 2022
Full Text: View/download PDF

49. Prédiction de la réponse a la chimiothérapie néoadjuvante du cancer du sein de phénotype luminal : apport du volume glycolytique total

Author: Groheux, David, Hatt, Mathieu, HINDIE, Elif, Giacchetti, Sylvie, De Cremoux, Patricia, Lehmann-Che, Jacqueline, Martineau, Antoine, Marty, Michel, Cheze-Le Rest, Catherine, DE ROQUANCOURT, A, VISVIKIS, Dimitris, Espie, Marc, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Optimisation Continue des Actions Thérapeutiques par l'Intégration d'Informations Multimodales, Université de Brest (UBO)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine nucléaire [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], CHU Poitiers - Département de médecine nucléaire (CHU Poitiers - Département de médecine nucléaire), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Direction Scientifique (DS), and Institut Mines-Télécom [Paris] (IMT)-Télécom Bretagne
Subjects: 03 medical and health sciences, 0302 clinical medicine, Radiological and Ultrasound Technology, Biophysics, Radiology, Nuclear Medicine and imaging, ComputingMilieux_MISCELLANEOUS, 3. Good health, 030218 nuclear medicine & medical imaging
Abstract: Objectifs.– Evaluer la valeur predictive de la TEP-FDG realisee a j21 de la radio-chimiotherapie (RCT) dans une population de patients atteints de carcinome epidermoide de l’œsophage (CEO) en utilisant des methodes d’analyse quantitative standard et une methode automatique d’imagerie parametrique (PI). Materiels et methodes.– Quarante-huit patients sur 57 atteints de CEO traites par RCT ont beneficie d’une TEP avant (TEP1) et a j21 de la CRT (TEP2) et d’une evaluation a trois mois et un an de la fin du traitement comprenant examen clinique, fibroscopie avec biopsies et TDM ou TEP-FDG. Ils ont ete classes en repondeur complet (RC) en l’absence de progression lors de l’evaluation ou en non repondeur complet (nRC). Une analyse semi-quantitative (SUVmax, SUVmoyen, Volume tumoral (V), et TLG) sur les TEP1 et TEP2 a ete realisee. Les variations entre les deux TEP ont ete comparees avec l’evolution a trois mois et un an. Avec PI pour chaque patient apres recalage a partir des donnees TDM, les donnees TEP sont soustraites voxel a voxel. On obtient 1 graphe biparametrique analyse par un modele de melange gaussien determinant les voxels dans lesquels des changements significatifs ont eu lieu. Des indices quantitatifs caracterisant ces changements sont obtenus (clusters vert ou rouges). Tous les parametres obtenus (par PI et par methode d’analyse classique) ont ete compares a l’etat clinique a trois mois et un an. Resultats.– SUVmax, SUVmoyen, V et TLG diminuent significativement entre les deux TEP (p 6,2 mL) etait le seul parametre significatif de nRC a trois mois (OR = 3,92, p= 0,0369) et un an (OR = 3,51, p= 0,0423). Conclusion.– Cette etude prospective multicentrique montre l’interet additionnel de la methode PI dans la caracterisation des changements tumoraux par rapport aux methodes d’analyse « classique » utilisant les SUV et V.
Published: 2013
Full Text: View/download PDF

50. Correlation between energy deposition and molecular damage from Auger electrons: A case study of ultra-low energy (5–18 eV) electron interactions with DNA

Author: Sanche, Léon [Groupe en Sciences des Radiations, Département de Médecine Nucléaire et Radiobiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4 (Canada)]
Published: 2014
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

647 results on '"Département de Médecine Nucléaire"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources